Registration Dossier

Administrative data

Key value for chemical safety assessment

Effects on fertility

Description of key information

Under the conditions of the two-generation reproduction toxicity study with 2 -Aminoethanol HCl, as structural analogue of 3 -Aminopropan-1-ol, the NOAEL for systemic toxicity and fertility in parental F0 and F1 Wistar rats is 300 mg/kg bw/day.

The NOAEL for pre-and postnatal developmental toxicity in their offspring is 1000 mg/kg bw/day.

Link to relevant study records
Reference
Endpoint:
two-generation reproductive toxicity
Type of information:
experimental study
Adequacy of study:
key study
Study period:
03 Aug 2006 - 15 Jan 2009
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
guideline study with acceptable restrictions
Reason / purpose for cross-reference:
reference to same study
Qualifier:
according to guideline
Guideline:
OECD Guideline 416 (Two-Generation Reproduction Toxicity Study)
Version / remarks:
Jan 2001
Deviations:
yes
Remarks:
Food consumption was not determined between days 14 and 21 after parturition
Qualifier:
according to guideline
Guideline:
EPA OPPTS 870.3800 (Reproduction and Fertility Effects)
Version / remarks:
Aug 1998
Qualifier:
according to guideline
Guideline:
other: Corrigendum to EC Commission Directive 2004/73/EC, Part B: Methods for the determination of toxicity: Two-Generation Reproduction Toxicity Study; Official Journal of the European Comm unities; No. L216, pp. 236–246
Version / remarks:
29 Apr 2004
GLP compliance:
yes (incl. QA statement)
Limit test:
no
Specific details on test material used for the study:
SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: ad 1) JB116/2+3 (from 09 Aug – 04 Oct 2006); ad 2) JB116/4 (from 04 Oct – 29 Nov 2006); ad 3) JB116/9-17
- Test substance Nos: 1) 05/0372-2; 2) 05/03723; 3) 05/0372-4

STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Room temperature, under N2
Species:
rat
Strain:
Wistar
Remarks:
Crl:WI (Han)
Details on species / strain selection:
The rat is the preferred animal species for reproduction studies according to test guidelines. This strain was selected since extensive historical control data were available for Wistar rats.
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Charles River Laboratories, Research Models and Services GmbH, Germany
- Females nulliparous and non-pregnant: yes
- Age at study initiation: (P) 44 (+/- 1) days
- Weight at study initiation: (P) Males: 162.1 (142.5 – 186.5) g; Females: 126.2 (110.6 – 145.1) g
- Fasting period before study: no
- Housing: rats were housed individually in type DK III stainless steel wire mesh cages supplied by Becker & Co., Castrop-Rauxel, Germany (floor area of about 800 cm²), with the following exceptions:
• overnight mating: male and female mating partners were housed together in type DK III cages
• gestation day 18 – lactation day 21: pregnant animals and their litters were housed in Makrolon type M III cages (floor area of about 800 cm²). The M III cages were also supplied by Becker & Co.
Pregnant females were provided with nesting material (cellulose wadding) toward the end of gestation.
- For enrichment wooden gnawing blocks (Typ NGM E-022, supplied by Abedd® Lab. and Vet. Service GmbH, Vienna, Austria) were added.
- Diet: ad libitum, ground Kliba maintenance diet mouse/rat “GLP” meal, supplied by Provimi Kliba SA, Kaiseraugst, Switzerland
- Water: ad libitum
- Acclimation period: 16 days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 30-70
- Air changes (per hr): 10-15
- Photoperiod (hrs dark / hrs light): 12/12
Route of administration:
oral: feed
Vehicle:
unchanged (no vehicle)
Details on exposure:
DIET PREPARATION
The test substance (ethanolamine hydrochloride, EAH) was weighed and thoroughly mixed with a small amount of food. Then corresponding amounts of food, depending on the dose group, were added to this premix in order to obtain the desired concentrations. Mixing was carried out for about 10 minutes in a laboratory mixer. Test diets were prepared at intervals, which guaranteed that the test substance in the diet remained stable throughout the feeding period.

During the first week of the premating period, F0 parental animals received dietary Ethanolamine hydrochloride (EAH) concentrations based on the body weight of randomization and historical food consumption data given below:
Food consumption males: 19 g
Food consumption females: 15 g
The dietary concentration of EAH was calculated using the following formula: BWx . D / FCx = ppm
where
BWx = mean body weight on day x [g]
D = desired dose [mg/kg body weight/day]
FCx = mean daily food consumption on day x [g]
ppm = dietary EAH concentration for the week/period following day x

- During the remaining premating period, the dietary concentrations of EAH were adjusted weekly for each group and sex based on body weight and food consumption measurements from the preceding
week.
- During the mating period of the F0 parental animals, each group and sex received the concentrations of EAH used during the last week of the premating period. This concentration was maintained throughout the mating period with the following exception: During cohabitation, both sexes received the test substance preparation for females as soon as the male was placed in the cage of its female partner. Both sexes returned to their normal test diet when they were separated the following morning. This test diet cycle remained in effect until there was evidence of successful mating. At that time, the mated animals received the test substance preparations described below at the first opportunity in the specific week.
- During the gestation period, dietary concentrations of EAH for the F0 males were again adjusted weekly on the basis of body weight and food consumption data from the preceding week. The EAH concentrations in the diet of the F0 females were the same as those used during the last week of the premating period.
- During the lactation period, dietary concentrations of EAH for the F0 males continued to be adjusted weekly on the basis of body weight and food consumption data from the preceding week. The EAH concentrations in the diet of the F0 females were 50% of those used during the last week of the premating period. This dietary adjustment, derived from historical body weight and food consumption data, maintained the dams at the desired doses of EAH during this period of increased food intake.
- Post weaning, dietary EAH levels for parental male animals awaiting necropsy were adjusted weekly based on body weight and food consumption data from the preceding week. The EAH concentration of parental female diets was the same as those used during the last week of the preceding premating period.

- Until all litters were weaned (when the last selected F1 pup reached age of day 21 p.p.), the food for the weaned F1 pups selected as F1 parental animals was prepared with EAH concentrations on the basis of historical body weight and food consumption data for rats of similar age.
- During the first week of the premating period of F1 parental animals, dietary EAH concentrations were formulated on the basis of actual body weight on day 0 and historical food consumption data. Subsequently, dietary EAH levels for each F1 dose group and sex were adjusted as described for F0 parental animals.
Details on mating procedure:
- M/F ratio per cage: 1/1
- Length of cohabitation: over night
- Proof of pregnancy: [sperm in vaginal smear] referred to as [day 0] of pregnancy
- After 14 days of unsuccessful pairing replacement of first male by another male with proven fertility.
- After successful mating each pregnant female was caged (how): individual

In general, male and female animals were mated overnight at a 1 : 1 ratio for a maximum of 2 weeks. Each female animal was paired with a predetermined male animal from the same dose group throughout the entire mating period. Mating was accomplished by placing the male in the cage of the female mating partner from about 4.00 p.m. until 7.00 - 9.00 a.m. of the following morning. Deviations from these specified times were possible on weekends and public holidays and were reported in
the raw data. A vaginal smear was prepared after each mating and was examined for the presence of sperm. If sperm were detected, pairing of the animals was discontinued. The day on which sperm were detected was denoted "day 0" and the following day "day 1" post coitum (p.c.).
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
The stability of EAH in the diet over 32 days at room temperature was investigated analytically before the beginning of the study. Homogeneity and concentration control analyses were carried out at the beginning and toward the end of the premating periods. At least one analysis of test substance preparations for female animals was carried out during the gestation and lactation periods.

The analyses were carried out at the Analytical Chemistry Laboratory of Experimental Toxicology and Ecology of BASF SE, Ludwigshafen, Germany.
Duration of treatment / exposure:
semichronic duration (> 75 days)
Frequency of treatment:
continuously
Details on study schedule:
F0 PARENTAL ANIMALS
After the acclimatization period, the F0 generation parental animals continuously received the test substance at the appropriate concentrations in the diet up to about 16 hours before they were sacrificed. At least 75 days after the beginning of treatment, males and females from the same dose group were mated. The females were allowed to litter and rear their pups (F1 generation pups) until day 4 (standardization) or 21 after parturition. After weaning of F1 pups the F0 generation parental animals were sacrificed.
F1 PARENTAL ANIMALS
After weaning, 25 males and 25 females of the F1 pups of test groups 00, 01, 02 and 03 (0, 100, 300 and 1000 mg/kg bw/d) were taken per group as the basis of the F1 generation parental animals. These animals were chosen by lot and it was attempted to take each litter into account. If fewer than 25 litters were available in a group or if one sex was missing in a litter, more animals were taken from the other litters of the respective test group to obtain the full number. All selected animals were treatedwith the test substance at the same dose level as their parents from their growth into adulthood up to about one day before they were sacrificed. At least 75 days after assignment of the F1 generation parental animals, the males and females were generally mated at a ratio of 1:1. Partners were randomly assigned, mating of siblings was excluded. The females were allowed to litter and rear their pups (F2 generation pups) until day 4 (standardization) or 21 after parturition. Shortly after the F2 generation pups had been weaned, the F1 generation parental animals were sacrificed.
STANDARDIZATION OF LITTERS (F1 AND F2 GENERATION PUPS)
On day 4 p.p., individual litters were standardized in such a way that, where possible, each litter contained 4 male and 4 female pups (always the first 4 pups/sex and litter were taken for further rearing). If it was not possible for individual litters to have 4 pups/sex, it was proceeded in such a way that 8 pups per litter were present for further rearing (e.g. 5 male and 3 female pups). Standardization of litters was not performed in litters with ≤ 8 pups.
PUPS AFTER STANDARDIZATION AND AFTER WEANING
After standardization or weaning, all pups were sacrificed by means of CO2 with the exception of those F1 generation pups, which were chosen as F1 generation parental animals. All sacrificed pups, including stillborn pups and those that died during their rearing period, were subject of a macroscopic (external and visceral) examination. All pups without any notable findings or abnormalities were discarded after their macroscopic evaluation.
Dose / conc.:
100 mg/kg bw/day (nominal)
Dose / conc.:
300 mg/kg bw/day (nominal)
Dose / conc.:
1 000 mg/kg bw/day (nominal)
No. of animals per sex per dose:
25
Control animals:
yes, plain diet
Positive control:
none
Parental animals: Observations and examinations:
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily on working days and once daily on weekends

DETAILED CLINICAL OBSERVATIONS: Yes

BODY WEIGHT: Yes
- Time schedule for examinations: body weights of F0 and F1 parents were determined once weekly; during gestation and lactation F0 and F1 females were weighed on days 0, 7, 14 and 20 of gestation, and on days 1, 4, 7, 14 and 21 after birth.

FOOD CONSUMPTION AND COMPOUND INTAKE: Yes
- Time schedule: once weekly (over a period of at least 6 days each) and weekly during gestation (days 0-7, 7-14, 14-20 post coitum; p.c.) and lactation periods (days 1-4, 4-7, 7-14 post partum; p.p.).

MALE REPRODUCTION DATA:
For every F0 and F1 breeding pair, following parameters were recorded: mating partners, number of mating days until positive evidence of sperm, and gestational status of the female.

FEMALE REPRODUCTION AND DELIVERY DATA:
For F0 and F1 females, following parameters were noted: mating partners, number of mating days until positive evidence of sperm, and gestational status.

BLOOD SAMPLINGS:
Blood samples were taken from all F0 and F1 parental animals of each sex and test group during week 10 of premating treatment and the plasma was analyzed for the concentration of the test substance.
Oestrous cyclicity (parental animals):
Estrous cycle data were evaluated for F0 and F1 generation females over a three week period prior to mating until evidence of mating occurred. Moreover, the estrous stage of each female was determined on the day of scheduled sacrifice.
Sperm parameters (parental animals):
Parameters examined in male parental generations:

Immediately after necropsy and organ weight determination, the right testis and cauda epididymidis were taken from the F0 and F1 males of all dose groups. The following parameters were determined:
- sperm head count in testis
- sperm head count in cauda epididymidis
- sperm morphology
- sperm motility
Preparation of specimens for sperm morphology and sperm motility examinations were carried out in a randomized sequence. To evaluate a possible effect on sperm parameters, sperm head count and sperm morphology were evaluated for the control and highest dose group (1000 mg/kg bw/day). Only in case of significant differences between these groups, additional sperm head counts were made for the mid-dose (300 mg/kg bw/day) and, if necessary, for the low-dose group (100 mg/kg bw/day) to reveal
the dose level affecting these parameters.
Litter observations:
STANDARDISATION OF LITTERS
- Performed on day 4 postpartum: yes

PUP NUMBER AND STATUS AT DELIVERY:
On the day of birth, all pups derived from the F0 parents (F1 litter) and the F1 parents (F2 litter) were examined as soon as possible to determine the total number of pups, and the number of liveborn as well as stillborn pups of each litter. Pups, which died before examination, were designated as stillborn pups.

PUP VIABILITY/MORTALITY:
- In general, a check was made for dead or moribund pups twice daily on workdays (once in the morning and once in the afternoon) and once in the morning on Saturdays, Sundays or public holidays. Dead pups were evaluated as dexribed in the section 'Postmortem examinations (offspring)'
- The number and percentage of dead pups on the day of birth (day 0) and of pups dying between days 1-4, 5-7, 8-14 and 15-21 of the lactation period were determined; however, pups, which died accidentally or had to be sacrificed due to maternal death, were not included in these calculations. The number of live pups/litter was calculated on the day of birth, and on lactation days 4, 7, 14, and 21.

SEX RATIO:
- On the day of birth (day 0 p.p.), the sex of the pups was determined by observing the distance between the anus and the base of the genital tubercle; normally, the anogenital distance is considerably greater in male than in female pups. Subsequently, the sex of the pups was assessed by the external appearance of the anogenital region and/or the mammary line and was finally confirmed at necropsy.
- The sex ratio was calculated at day 0 and day 21 p.p. according to the following formula:
Sex ratio = (number of live male or female pups on day 0/day 21 p.p. / number of live male and fema
le pups on day 0/day 21 p.p.) X 100

PUP CLINICAL OBSERVATIONS:
The live pups were examined daily for clinical symptoms (including gross-morphological findings) during the clinical inspection of the dams. If pups showed any special findings, these were documented with the dam concerned.

PUP BODY WEIGHT DATA:
The pups were weighed on the day after birth (day 1 p.p.) and on days 4 (before standardization), 7, 14 and 21 after birth. Pups' body weight change was calculated based on these results. The individual weights were always determined at about the same time of the day (in the morning) and on day 4 p.p. immediately before standardization of the litters.

SEXUAL MATURATION:
- Vaginal opening: All female F1 pups selected to become the F1 parental generation females (25/group) were examined daily for vaginal opening beginning on day 27 p.p. On the day of vaginal opening, the body weights of the respective animals were additionally determined.
- Preputial separation: All male F1 pups selected to become the F1 parental generation males (25/group) were examined daily for preputial separation beginning on day 40 p.p. On the day of preputial separation, the body weights of the respective animals were additionally determined.

ASSESSMENT OF DEVELOPMENTAL NEUROTOXICITY: No

ASSESSMENT OF DEVELOPMENTAL IMMUNOTOXICITY: No
Postmortem examinations (parental animals):
All F0 and F1 parental animals were sacrificed by decapitation under Isoflurane anesthesia. The exsanguinated animals were necropsied and assessed by gross pathology, special attention was given to the reproductive organs. As soon as possible after termination, one portion of the liver (lobus medialis) of each 10 dams per group was sampled to be analyzed for choline concentration.

ORGAN WEIGHTS:
Weight assessment was carried out on all animals sacrificed at scheduled dates. The following weights were determined:
1. Anesthetized animals, 2. Liver, 3. Kidneys, 4. Adrenal glands, 5. Testes, 6. Epididymides, 7. Cauda epididymis, 8. Prostate, 9. Seminal vesicles including coagulation glands, 10. Ovaries, 11. Uterus, 12.Spleen, 3. Brain, 14. Pituitary gland, 15. Thyroid glands (with parathyroid glands).

ORGAN/TISSUE FIXATION:
The following organs or tissues of the F0 and F1 generation parental animals were fixed in 4% neutral buffered formaldehyde solution or in BOUIN’s solution, respectively:
1. Vagina, 2. Cervix uteri, 3. Uterus, 4. Ovaries (fixed in BOUIN´s solution), 5. Oviducts, 6. Left testis (fixed in BOUIN´s solution), 7. Left epididymis (fixed in BOUIN´s solution), 8. Seminal vesicles, 9. Coagulation glands, 10. Prostate, 11. Pituitary gland, 12. Adrenal glands, , 3. Liver, 14. Kidneys, 15.Spleen, 16. Brain, 17. Thyroids (with parathyroids), 18. All gross lesions. After fixation, the organs fixed in BOUIN´s solution were embedded in Paraplast. Fixation was followed by histotechnical proces
sing, examination by light microscopy and assessment of findings. All gross lesions were examined. Of the fixated organs the organs of all animals in the control group and the high dose group were evaluated. Additionally, the organs for mating pair suspected of reduced fertility were evaluated.

DIFFERENTIAL OVARIAN FOLLICLE COUNT (DOFC) IN F1 GENERATION:
From both ovaries (”ovary 1” and “ovary 2”) of F1 female animals (control and top dose), five sections were taken from the proximal and the distal part of the ovaries, respectively, at least 100 μm apart from the inner third of the ovary. All ovarian sections were prepared and evaluated. Primordial follicles and growing follicles were counted by light microscope (magnification: 100x) on each of these slides, – according to the definitions given by Plowchalk et al. (PLOWCHALK, D. R., B. J. SMITH, and
D. R. MATTISON: Assessment of Toxicity to the Ovary Using Follicle Quantitation and Morphometrics. In: Methods in Toxicology, Vol. 3, Part B: Female Reproductive Toxicology (J. J. HEINDEL and R. E. CHAPIN, Editors), p. 57-68, 1993, Academic Press). To prevent multiple counting on serial slides – especially of the growing follicles – only follicles with an oocyte with visible chromatin on the slide were counted. The number of each type of follicle was recorded individually for ovary 1 and ovary 2 of every animal on any of the slide levels (level 1-10), giving in summary the incidence of each type of the follicles by using EXCEL sheets for the reporting of the results. Finally, the results of all types of follicles were summarized for all animals per group in dose groups 10 and 13. As primordial follicles continuously develop into growing follicles, the assessment of the follicles was extended to the combined incidence of primordial plus growing follicles. In general, the fifth slide of the left and right ovary was evaluated for histological findings. A correlation between gross lesions and histopathological findings was performed.
Postmortem examinations (offspring):
PUP ORGAN WEIGHTS:
After scheduled sacrifice brain, spleen and thymus of 1 pup/sex and litter from the F1 and F2 pups were weighed. Normally, the first male and the first female pups/litter were taken for these examinations. For the calculation of the respective relative organ weights, pup body weights were taken, which were determined routinely during the in-life phase on day 21 p.p.
PUP NECROPSY OBSERVATIONS:
All pups with scheduled sacrifice (i.e. pups, which were culled on day 4 p.p., and pups, which were sacrificed on day 21 p.p. or subsequent days) were killed by means of CO2. All pups were examined externally and eviscerated; their organs were assessed macroscopically. All stillborn pups and all pups that died up to weaning were examined externally, eviscerated and their organs were assessed macroscopically. All pups without any notable findings or abnormalities were discarded after their macroscopic evaluation.
Statistics:
see in 'Any other information on materials and methods incl. tables'.
Reproductive indices:
For the males, mating and fertility indices were calculated for F1 and F2 litters according to the following formulas:
- Male mating index (%) = (number of males with confirmed mating / number of males placed with females) x 100
- Male fertility index (%) = (number of males proving their fertility / number of males placed with females) x 100
The number of males with confirmed mating was defined by a femal with vaginal sperm or with implants in utero.
The number of males proving their fertility was defined by a female with implants in utero.
For females, mating, fertility and gestation indices were calculated for F1 and F2 litters according to the following formulas:
- Female mating index (%) = (number of females mated / total number of pups born) x 100
- Female fertility index (%) = (number of females pregnant / number of females mated) x 100
- Gestation inex (%) = (number of females with live pups on the day of birth / number of females pregnant) x 100
The number of females mated was defined as the number of females with vaginal sperm or with implants in utero.
The number of females pregnant was defined as the number of females with implants in utero.
The total amount of delivered pups/dam was recorded and the number of liveborn and stillborn pups
noted. The live birth index was calcualted for F1 and F2 litters according to the following formula:
- Live birth index (%) = (number of liveborn pups at birth / total number of pups born) x 100
The implantations were counted and the postimplantation loss (in %) was calculated according the following formula:
Postimplantation loss (%) = ((number of implantations – number of pups delivered) / number of
implantations) x100
Offspring viability indices:
Viability and lactation indices were calculated according to the following formulas:
- Viability index (%) = (number of live pups on day 4 (before standardization of litters) after birth /number of live pups on the day of birth) x 100
- Lactation index (%) = (number of live pups on day 21 after birth / number of live pups on day 4(after standardization of litters) after birth) x 100
Clinical signs:
effects observed, treatment-related
Description (incidence and severity):
No clinical signs or changes of the general behavior, which may be attributed to the test substance, were detected in male or female parental animals of the test groups 100 and 300 mg/kg bw/day. Intensively yellow discolored urine was recorded in all males and females of test group 1000 mg/kg bw/day from study week 3 onwards until the end of the treatment period. This urine discoloration mirrored the systemic availability of the test substance rather than being an adverse effect and was most likely caused by the excreted test compound and/or its metabolites.
Dermal irritation (if dermal study):
not examined
Mortality:
no mortality observed
Description (incidence):
There were no unscheduled mortalities of male and female parental animals in any test group.
Body weight and weight changes:
effects observed, treatment-related
Description (incidence and severity):
Mean body weights and average body weight gain of the P0 parental males of all test substancetreated groups (100, 300 and 1000 mg/kg bw/d) were comparable to the controls throughout the entire study period. Observed differences between controls and test groups were regarded as spontaneous in nature. During premating, gestation and lactation periods, the mean body weights and body weight gains of the P0 parental females in the low- and mid-dose groups were generally comparable to the concurrent control group. During premating, gestation and lactation periods, the mean body weights and body weight gains of the P0 parental females in the low- and mid-dose groups were generally comparable to the concurrent control group. Mean body weights and body weight gains of the P0 females in test group 03 (1000 mg/kg bw/d) were similar to the controls throughout the entire premating period. During gestation, these animals gained less weight from gestation day 7 onwards (up to 38%). As a consequence, body weights on gestation day 20 were 8% lower than the control. This effect may have been caused by the statistically significantly increased postimplantation loss and the statistically significantly decreased mean number of delivered pups in test group 03. This is also indicated by the unaffected body weight of the high dose dams on post-delivery day 1. Mean body weights of the high-dose females remained comparable to the controls during entire lactation, whereas the weight gain wavered up and down in the individual lactation sections.
Food consumption and compound intake (if feeding study):
effects observed, treatment-related
Description (incidence and severity):
Food consumption of the P0 parental males of all test substance-treated groups was generally comparable to the controls throughout the entire study. The statistically significant increase of food consumption in test group 02 (300 mg/kg bw/day) during study week 12-13 was regarded as spontaneous in nature. Food consumption of the F0 parental females of the low- and mid-dose groups (100 and 300 mg/kg bw/day) was comparable to the control animals during the periods of premating, g
station and lactation. Food consumption of the high-dose F0 females (1000 mg/kg bw/d) was also comparable during premating and gestation periods. However, in these animals, food consumption
was statistically significantly below controls (up to 18%) in the individual lactation sections: days 1-4, 4-7, and 7-14 p.p.
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Behaviour (functional findings):
not examined
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
effects observed, treatment-related
Histopathological findings: non-neoplastic:
effects observed, non-treatment-related
Description (incidence and severity):
- Extramedullar hematopoiesis was seen in the spleen of 1000 mg/kg male animals in a slightly higher number of animals compared to control animals, but only in a minimal (grade 1) to slight (grade 2) severity. A treatment-related increase seems unlikely, because no weight deviations were observed, the severity was very low and comparable to the control animals. All other findings noted were single observations either, or were similarly in distribution pattern and severity in control rats compared to treatment groups. All of them are considered to be incidental and/or spontaneous in origin and without any relation to treatment.
- Fertility: The non-pregnant female and the male mating partner did not show histopathological findings explaining the infertility. Only a minimal focal atrophy of the prostate was present, which is considered an incidental finding.
Histopathological findings: neoplastic:
no effects observed
Reproductive function: oestrous cycle:
no effects observed
Description (incidence and severity):
Estrous cycle data, generated during the last 3 weeks prior to mating for the F1 litter, revealed regular cycles in the females of all test groups including the control. For the different test groups, the mean estrous cycle duration varied between 3.8 (test group 01) and 3.9 days (test groups 00, 02 and 03).
Reproductive function: sperm measures:
effects observed, non-treatment-related
Description (incidence and severity):
- For most sperm parameters examined in the P0 parental males no treatment-related effects were noted. The number of homogenization resistant testicular spermatids, the percentages of abnormal and normal sperm and sperm motility data were comparable between the test substance-treated groups and the concurrent control and did not show any statistically or biologically significant differences. However, the number of homogenization resistant caudal epididymal sperm was statistically significantly reduced in test group 03 (1000 mg/kg bw/day) compared to the control (-13% [p≤0.05]). Hence, the number of caudal epididymal sperm in test group 02 (300 mg/kg bw/day) was additionally evaluated revealing values comparable to the control.
- For all groups, including the control, it has to be noted that the mean amount of sperm in the cauda epididymidis was below the test facility’s historical control data.
Reproductive performance:
effects observed, treatment-related
Description (incidence and severity):
MALE REPRODUCTION DATA:
- Cohabitation was confirmed for all P0 parental males, which were paired with females to generate F1 pups. Thus, the male mating index was 100% in all test groups.
- Fertility was proved for most of the P0 parental males with confirmed cohabitation. One high-dose male (1000 mg/kg bw/day) did not generate F1 pups although its individual sperm parameters did not show any difference to control animals. Thus, the male fertility index was 100% for the test groups 00-02 and 96% for test group 03. These values reflect the normal range of biological variation inherent in the strain of rats used for this study. All respective values were within the range of the historical control data of the test facility.
FEMALE REPRODUCTION AND DELIVERY DATA:
- The female mating index calculated after the mating period for F1 litter was 100% in all test groups. The mean duration until sperm was detected (day 0 p.c.) varied between 2.4 and 2.6 days without any relation to dosing. Nearly all sperm positive females delivered pups or had implants in utero. One high-dose P0 female did not become pregnant. Consequently, the fertility index varied between 96% (test group 03) and 100% (test groups 00-02).
- The mean duration of gestation was comparable between all test groups. The respective values were 21.8, 21.8, 21.7 and 22.2** (p≤0.01) days. Although the duration of gestation appeared to be statistically significantly increased in the high-dose group, this value was only slightly above the concurrent control and was still within the historical control range of the test facility (21.5–22.3 days). Therefore, this finding was not considered to be treatment-related.
- The gestation index was 100% in test groups 00, 01 and 03 (0, 100, 1000 mg/kg bw/d), indicating that all pregnant F0 females in these test groups had live F1 pups in their litters. The gestation index was 96% in test group 02 (300 mg/kg bw/d), caused by one female, which delivered no pups, but had 2 implants in utero.
- With regard to the number of implantation sites, no statistically significant differences were seen between the control (11.8 implants/dam) and test groups 01 and 02 (12.4 and 11.8 implants/dam, respectively). In contrast, the number of implantation sites was statistically significantly reduced in test group 03 (8.6** [p≤0.01]). Furthermore, there were indications for test substance-induced intrauterine embryo-/fetolethality, since the postimplantation loss was statistically significantly increased in the high-dose group (23.0%** [p≤0.01] at 1000 mg/kg bw/d). There were no statistically significantly differences concerning the postimplantation loss between the remaining test groups and the control (5.7%, 6.8% and 9.9% at 0, 100 and 300 mg/kg bw/d, respectively).
- The average litter size (F1 pups per dam) was very similar between test groups 00, 01 and 02 (11.1, 11.4, and 11.4 pups/dam, respectively). A statistically significantly lower number of F1 pups per dam were delivered in test group 03 (6.8** pups/dam [p≤0.01]). Since the number of stillborn pups was comparably low in all groups, the live birth index was 99% for test groups 00, 02 and 03, and 100% for test group 01.
PLASMA CONCENTRATIONS
The analysis of the plasma concentrations of Ethanolamine (calculated as Ethanolamine hydrochlorid) showed concentrations below 3 [mg/kg] for all control animals of both sexes for the P0 and the F1 generation. The low-dose groups resulted in values of <3 - 4 [mg/kg] for the male animals of the P0 generation and was below 3 [mg/kg] for the female animals of the P0 and for the male and female animals of the F1 generation. The mean plasma concentrations of Ethanolamine (calculated as Ethanolamine hydrochlorid) of the animals of the mid dose were 8, 9, 11 and 10 [mg/kg] for the male animals of the P0 and the F1 generation and for the female animals of the P0 and the F1 generation, respectively. The mean plasma concentrations of Ethanolamine (calculated as Ethanolamine hydrochlorid) of the animals of the high dose were 65, 60, 66 and 81 [mg/kg] for the male animals of the F0 and the F1 generation and for the female animals of the P0 and the F1 generation, respectively. These data show a dose dependency of the plasma levels of Ethanolamine in the experimental
animals and therewith prove the bioavailability of Ethanolamine hydrochloride in principle.
Key result
Dose descriptor:
NOAEL
Remarks:
systemic toxicity
Effect level:
300 mg/kg bw/day (nominal)
Based on:
test mat.
Sex:
male/female
Basis for effect level:
body weight and weight gain
food consumption and compound intake
reproductive function (sperm measures)
reproductive performance
Key result
Dose descriptor:
NOAEL
Remarks:
reproductive toxicity
Effect level:
1 000 mg/kg bw/day (nominal)
Based on:
test mat.
Sex:
male
Basis for effect level:
reproductive function (sperm measures)
Remarks on result:
not determinable
Remarks:
no clear evidence of treatment-related effects
Key result
Dose descriptor:
NOAEL
Remarks:
reproductive toxicity
Effect level:
300 mg/kg bw/day (nominal)
Based on:
test mat.
Sex:
female
Basis for effect level:
reproductive performance
Remarks on result:
other: occurring together with systemic toxicity
Key result
Critical effects observed:
no
Clinical signs:
effects observed, non-treatment-related
Description (incidence and severity):
No clinical signs or changes in general behavior, which may be attributed to the test substance, were detected in F1 male or F1 female parental animals of the test groups 11 and 12 (100 and 300 mg/kg bw/day).
Intensively yellow discolored urine was recorded in all F1 males and F1 females of test group 13 (1000 mg/kg bw/day) from study week 0 onwards until the end of the treatment period. This urine discoloration mirrored the systemic availability of the test substance rather than being an adverse effect and was most likely caused by excreted test compound and/or its metabolites. Furthermore, one F1 male animal of test group 11 (100 mg/kg bw/day) had a skin lesion at its throat during study weeks 3-6.
Clinical observations for females during gestation of F2 litters:
All F1 females of test group 1000 mg/kg bw/day showed intensively yellow discolored urine during the entire gestation period (F2 litter). No other clinical findings were observed in the test groups 10-13 (0, 100, 300 and 1000 mg/kg bw/day). One sperm-positive female of test group 10 (control), one of test group 11 (100 mg/kg bw/day) and two of test group 13 (1000 mg/kg bw/day) did not deliver F2 pups. These observations were not considered to be associated to the test compound due to a missing dose-response relationship.
Clinical observations for females during lactation of F2 litters: All F1 females of test group 13 showed intensive yellow discolored urine during the entire lactation period for F2 litters. No other clinical findings were observed in the test groups 10-13 (0, 100, 300 and 1000 mg/kg bw/day).
Dermal irritation (if dermal study):
no effects observed
Mortality:
no mortality observed
Description (incidence):
None of the male and female F1 parental animals of any test group died ahead of schedule.
Body weight and weight changes:
effects observed, treatment-related
Description (incidence and severity):
- Mean body weights and body weight gain of the F1 parental males in test groups 11-13 (100, 300 and 1000 mg/kg bw/day) were comparable to the control throughout the entire treatment period. The statistically significantly decreased values of body weight gain in the high-dose males during study weeks 6-7 and 9-10 were in the normal range of fluctuation of this group and the control during the course of the study and, therefore, regarded as incidental.
- Mean body weights and body weight gain of the F1 parental females in test groups 11-12 (100 and 300 1000 mg/kg bw/day) were comparable to the control throughout premating, gestation and lactation periods. Mean body weights and body weight gains of the F1 females in test group 03 (1000 mg/kg bw/day) were similar to the controls throughout the entire premating period, the statistically significantly increased body weight gain of the high-dose F1 females (1000 mg/kg bw/day) during premating week 1-2 was regarded as incidental variance.
- The average weight gain of these animals was significantly below control (26%) during gestation days 14-20, which led to an averaged decrease of weight gain for the entire gestation of 17%. This effect may have been caused by the statistically significantly increased postimplantation loss and the statistically significantly decreased mean number of delivered pups in test group 03. Mean body weights of the high-dose females remained comparable to the controls during entire lactation.
Food consumption and compound intake (if feeding study):
effects observed, treatment-related
Description (incidence and severity):
Food consumption of F1 male and female animals in test groups 11-12 (100, and 300 mg/kg bw/day) was generally comparable to the control group throughout the entire treatment period, covering premating, gestation and lactation periods. Food consumption of the high-dose F0 females (1000 mg/kg bw/day) was also comparable during premating and gestation periods. However, in these animals, food consumption was statistically significantly below controls (-11%) on lactation days 1-4, and remained below control on lactation days 4-7 and 7-14 (-7%), although not statistically significant.
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Behaviour (functional findings):
not examined
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
effects observed, treatment-related
Description (incidence and severity):
1000 mg/kg bw/day: Statistically significantly decreased absolute and relative weight of epididymides and cauda epididymidis in males. The observed increase of absolute kidney weights of male and female animals in mid (300 mg/kg bw/day) and top dose (1000 mg/kg bw/day) groups, respectively, was statistically significant. Because no histomorphological correlate was detected, a treatment-related weight increase is less likely. The observed decrease of spleen weights in top dose males as well as the increase of thyroid glands in top dose males and mid and top dose females, respectively, is considered incidental and not treatment related due to a missing dose response relationship and no histopathological correlates.
Gross pathological findings:
no effects observed
Description (incidence and severity):
- All gross lesions observed in test animals occurred singularly. They are considered to be spontaneous lesions in origin and are not related to treatment.
- Fertility: One non-pregnant female animal did show a bilaterally severe reduced size of the ovaries as well as a moderate thickening of the uterus wall. The other three non-pregnant females did not show any gross lesions. The four male mating partners did not show any gross lesions either.
Neuropathological findings:
not examined
Histopathological findings: non-neoplastic:
effects observed, non-treatment-related
Description (incidence and severity):
- As compared to control animals, the kidneys of low, mid, and top dose male and female animals revealed a low incidence of basophilic tubules in a slightly higher number of animals. The severity (minimal to slight) was comparable between controls and treated animals and a clear dose-response relationship was missing. The cauda epididymis and epididymides of top dose males showed no histomorphological correlates to the decreased organ weights. All other findings noted were single observations either, or were similarly in distribution pattern and severity in control rats compared to treatment groups. All of them are considered to be incidental and/or spontaneous in origin and without any relation to treatment.
- Fertility: One non-pregnant female showed a bilateral moderate diffuse stromal hyperplasia and a unilateral severe focally extensive chronic inflammation of the ovaries as well as an ovarian cyst. There were still corpora lutea present and the histopathological findings did not correlate with the gross lesion. The gross lesion “thickening of uterine wall” had no corresponding histological finding. The findings on the ovaries might explain the infertility. The male mating partner did not reveal lesions affecting the fertility. One female Animal showed within the uterus a severe multifocal endometrial and glandular degeneration and within the oviducts a severe diffuse epithelial degeneration, which explains the infertility of this animal. The male mating partner did not reveal lesions affecting the fertility. The other two mating pairs did not show any lesions affecting the fertility.
Histopathological findings: neoplastic:
no effects observed
Other effects:
no effects observed
Description (incidence and severity):
The results of the differential ovarian follicle count (DOFC) – comprising the numbers of primordial and growing follicles, as well as the combined incidence of primordial plus growing follicles – did not reveal significant deviations between controls and animals of the top dose group.
Reproductive function: oestrous cycle:
no effects observed
Description (incidence and severity):
Evaluation of the estrous cycle data, 3 weeks prior to mating for the F2 litter, revealed very regular cycles in the females of all test groups including the control. The mean estrous cycle duration varied between 3.8 days in test groups 11 and 12 and 3.9 days in test groups 10 and 13.
Reproductive function: sperm measures:
no effects observed
Description (incidence and severity):
No treatment-related effects were noted for the different sperm parameters, examined at or after the sacrifice of the F1 parental males. after the sacrifice of the F1 parental males. The number of homogenization resistant testicular spermatids as well as caudal epididymal sperm, the percentages of abnormal and normal sperms and sperm motility data were comparable between the examined test substance-treated groups and the concurrent control group (0, 100, 300 and 1000 mg/kg bw/ d). For all groups, including the control, it has to be noted that the mean sperm counts in the cauda epididymidis were below the test facility’s historical control data.
Reproductive performance:
effects observed, treatment-related
Description (incidence and severity):
MALE REPRODUCTION DATA:
- Cohabitation was confirmed for all F1 parental males, which were paired with females to generate F2 pups. Thus, the male mating index was 100% in all test groups.
- Fertility was proven for most of the F1 parental males with confirmed cohabitation. One control male, one low-dose male and two high-dose males did not generate F2 pups. Thus, the male fertility indices were 92% in test group 13 (1000 mg/kg bw/day), 96% in test groups 10 and 11 (0 and 100 mg/kg bw/day) and 100% in test group 12 (300 mg/kg bw/day). These values reflected the normal range of biological variation inherent in the strain of rats used for this study. In addition, these data were within the range of the historical control data of the test facility. None of the apparently infertile males showed corroborative histopathological findings, which could explain the observed infertility.
FEMALE REPRODUCTION AND DELIVERY DATA:
- The female mating index for F2 litter was 100% in all test groups.
- The mean duration until sperm was detected (day 0 p.c.) varied between 2.3 and 2.7 days without any relation to dosing.
- All sperm-positive rats delivered pups with the following exceptions: one control female, one female of test group 11 (100 mg/kg bw/d0 and two females of test group 13 (1000 mg/kg bw/d) did not become pregnant. Consequently, the fertility index was 92% for test group 13 (1000 mg/kg bw/day), 96% for test groups 10 and 11 (0 and 100 mg/kg bw/day) and 100% for test group 12 (300 mg/kg bw/d). These values reflect the normal range of biological variation inherent in the strain of rats used for this study.
- The mean duration of gestation was comparable in all test groups (10-13) and varied between 21.8 and 22.1.
- The gestation index was 100% for all test groups, indicating that all pregnant F1 females had live F2 pups in their litters.
- Implantation was clearly affected by the treatment, since the number of implantation sites was statistically significantly reduced in test group 13 (8.8** [p≤0.01] versus 11.3 implants/dam in control).There were no statistically significant differences in the number of implantation sites between test groups 11 and 12 (11.6 and 11.8 implants/dam, respectively) and the control. Furthermore, there were indications for test substance-induced intrauterine embryo-/fetolethality, since the postimplantation
loss was statistically significantly increased in the high-dose group (12.8* [p≤0.05] – 1000 mg/kg bw/day). In addition, the postimplantation loss in this test group was higher than documented in the historical control data. There were no statistically significantly differences concerning the postimplantation loss between the remaining test groups and the control (4.9%, 3.0%, and 4.0% for 0, 100, and 300 mg/kg bw/day, respectively).
- The average litter size (F2 pups per dam) was very similar between test groups 10, 11 and 12. A statistically significantly lowered number of F2 pups per dam were delivered in test group 13 (7.7**pups/dam [p≤0.01] versus 10.8, 11.2, and 11.4 in test groups 10, 11 and 12, respectively). The number of liveborn and stillborn pups was comparable between all groups, and the live birth index varied between 99% and 100%.
Key result
Dose descriptor:
NOAEL
Remarks:
systemic toxicity
Effect level:
300 mg/kg bw/day (nominal)
Based on:
test mat.
Sex:
male/female
Basis for effect level:
body weight and weight gain
food consumption and compound intake
organ weights and organ / body weight ratios
Key result
Dose descriptor:
NOAEL
Remarks:
reproductive toxicity
Effect level:
1 000 mg/kg bw/day (nominal)
Based on:
test mat.
Sex:
male
Basis for effect level:
reproductive performance
Key result
Dose descriptor:
NOAEL
Remarks:
reproductive performance
Effect level:
300 mg/kg bw/day (nominal)
Based on:
test mat.
Sex:
female
Basis for effect level:
reproductive performance
Key result
Critical effects observed:
no
Clinical signs:
effects observed, non-treatment-related
Description (incidence and severity):
One low-dose pup showed a kinked tail on lactation day 21, which was confirmed by skeletal examination (misshapen caudal vertebra, cartilage changed). For one high-dose pup microphthalmia of the left eye was recorded on lactation day 21 and was confirmed by visceral examination. These indivisual finding were assumed to be incidental and can also be found in the historical control data.
Dermal irritation (if dermal study):
not examined
Mortality / viability:
mortality observed, non-treatment-related
Description (incidence and severity):
- The mean number of F1 pups/dam was statistically significantly reduced in test group 03 (6.8** pups/dam [p≤0.01]). However, the number of stillborn F1 pups was comparable between the test groups 00, 01, 02, and 03 (2, 1, 2, and 2 pups/test group, respectively). Every stillborn pup belonged to a different litter.
- The viability index as indicator for pup mortality between days 0-4 p.p. was unaffected and varied between 99% (control group as well as test groups 01 and 03) and 100% (test group 02). However, cannibalized pups were found in test group 01 (3 pups), 02 (1 pup) and 03 (3 pups* [p≤0.05]). In this case, the calculated statistically significant difference for the highdose group was a consequence of the smaller litter sizes there. No pup was cannibalized in the control group.
- The lactation index, indicating pup mortality between days 4-21 p.p., was slightly, but statistically significantly lower in test group 01 (97%* [p≤0.05]). This value is, however, within the historical control range of the test facility. Thus, pup mortality in the low dose group during the lactation period was not considered to be associated to test substance-treatment. For the other test groups, the lactation index was 98% (test group 03) and 100% (test groups 00 and 02).
Body weight and weight changes:
effects observed, treatment-related
Description (incidence and severity):
Mean body weights of F1 male and female pups in test group 03 (1000 mg/kg bw/day) were statistically significantly increased during the complete lactation period, being marginally outside the range of historical control data. Body weight gain of these animals was statistically significantly increased between lactation days 1-4 (about 19%). Afterwards the weight gain of the high-dose animals was similar to the concurrent control group. The higher pup body weights in test group 03 were rather re
garded as a consequence of the reduced number of pups/litter than a direct test substance-related effect. No test compound-related influence on F1 pup body weights was noted in the low- and mid dose groups (100 and 300 mg/kg bw/day).
Food consumption and compound intake (if feeding study):
not examined
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Sexual maturation:
no effects observed
Description (incidence and severity):
- The sex distribution and sex ratios of live F1 pups on the day of birth and on day 21 p.p. did not show substantial differences between the control and the test substance-treated groups; slight differences were regarded to be spontaneous in nature.
- Vaginal opening: Each female F1 pup, which was selected to become a F1 parental animal, was evaluated for commencement of sexual maturity. The first day, when vaginal opening was observed, was day 27 p.p., the last was day 37 p.p. The mean number of days to reach the criterion in the test groups 00-03 amounted to 32.4, 31.8, 31.8, and 32.3 days (0, 100, 300 and 1000 mg/kg bw/day, respectively), indicating that female sexual maturation was not influenced by the test substance at any dose
level. The mean body weight on the day, when vaginal opening was noted, amounted to 95.1, 94.1, 95.0, and 97.6 grams in test groups 00-03
- Preputial separation: Each male F1 pups, which was selected to become a F1 parental animal, was evaluated for commencement of sexual maturity. The first day, when preputial separation was observed, was day 40 p.p., the last was day 48 p.p. The mean number of days to reach the criterion in test groups 00-03 amounted to 42.2, 42.5, 41.9, and 42.8 (0, 100, 300 and 1000 mg/kg bw/d, respectively), indicating that the test substance did not influence male sexual maturation at any dose level.
The mean body weight on the day, when preputial separation was recorded, amounted to 172.1, 173.7, 168.9, and 176.2 grams in test groups 00-03.
Organ weight findings including organ / body weight ratios:
effects observed, non-treatment-related
Description (incidence and severity):
- Absolute pup organ weights: Statistically significant changes in mean pup organ weights were only observed for the brain. The absolute mean pup brain weight was increased in high-dose (1000 mg/kg bw/day) F1 pups (males + females: +2.9% [p≤0.01]), especially in the males (+3.5% [p≤0.01]). All other mean absolute pup organ weights of the F1 pups did not show statistically significant differences to the organ weights of the control animals. The statistically significantly increased absolute brain weight
s of the high-dose F1 pups (1000 mg/kg bw/day) were assessed as secondary to the higher pup body weights in this group as proven by calculated the mean relative pup organ weights. The finding was neither adverse nor toxicologically relevant.
- Relative pup organ weights: Mean relative pup organ weights of the F1 pups did not show statistically significant differences to the control group.
Gross pathological findings:
effects observed, non-treatment-related
Description (incidence and severity):
At gross necropsy, a number of common findings were seen in F1 pups, such as partly cannibalized pups, post mortem autolysis, incisors sloped, microphthalmia, hemorrhagic thymus, abnormal liver lobation, empty stomach and kinked tail.
If all findings were considered together, the litter incidence and number of affected pups/litter were statistically significantly increased in test group 01 (100 mg/kg bw/day) and test group 03 (1000 mg/kg bw/day). However, each individual finding was observed only in single animals and/or can be found in the historical control data at comparable or even higher incidences. There was no evidence of a particular pattern, which might be related to a possible mode of action of the test compound. The low- (100 mg/kg bw/day) and high-dose (1000 mg/kg bw/day) litter incidences (12% and 17%, respectively) and rates of affected pups/litter with necropsy findings (1.2% and 2.7%, respectively) were clearly within the historical control data of the test facility (litter incidence: 4–52%; affected pups/litter: 0.5– 15.2%). Thus, these findings were considered as incidental and not related to treatment.
Histopathological findings:
not examined
Behaviour (functional findings):
not examined
Developmental immunotoxicity:
not examined
Key result
Dose descriptor:
NOAEL
Generation:
F1
Effect level:
1 000 mg/kg bw/day (nominal)
Based on:
test mat.
Sex:
male/female
Basis for effect level:
other: pre-and postnatal developmental toxicity
Key result
Critical effects observed:
no
Clinical signs:
no effects observed
Description (incidence and severity):
The F2 generation pups did not show any clinical signs up to weaning.
Dermal irritation (if dermal study):
not examined
Mortality / viability:
mortality observed, non-treatment-related
Description (incidence and severity):
The viability index as indicator for pup mortality between days 0-4 p.p. was 100% in all test groups. The lactation index as indicator for pup - The mean number of F2 pups/dam was statistically significantly reduced in test group 13 (1000 mg/kg bw/day). However, a comparison of the total amount of liveborn and stillborn F2 pups per test group did not reveal statistically significant differences between test groups 10- 13.
- The viability index as indicator for pup mortality between days 0-4 p.p. was 100% in all test groups.
- The lactation index as indicator for pup mortality between days 4-21 p.p. was not affected by test substance-treatment as it reached 100%, 100%, 99%, and 100% at dose levels of 0, 100, 300, and 1000 mg/kg bw/d. Any isolated pup deaths were assessed as incidental.mortality between days 4-21 p.p. was not affected by test substance-treatment as it reached 100%, 100%, 99%, and 100% at dose levels of 0, 100, 300, and 1000 mg/kg bw/d. Any isolated pup deaths were assessed as incidental.
Body weight and weight changes:
effects observed, non-treatment-related
Description (incidence and severity):
Mean body weights of F2 male and female pups in test groups 11-13 (100, 300 and 1000 mg/kg bw/day) were generally comparable to the concurrent control group throughout the entire lactation period. The statistically significantly increased body weights of female pups and the statistically significantly increased body weight value for both sexes in test group 13 on lactation day 1 were related to the decreased litter sizes and, given that, regarded to be secondary effects.
Food consumption and compound intake (if feeding study):
not examined
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Sexual maturation:
no effects observed
Description (incidence and severity):
The sex distribution and sex ratios of live F2 pups on the day of birth and on day 21 p.p. did not show substantial differences between the control and the test substance-treated groups; slight differences were regarded to be spontaneous in nature.
Organ weight findings including organ / body weight ratios:
no effects observed
Description (incidence and severity):
No treatment-related pup organ weight changes concerning absolute and relative brain, thymus and spleen weights were seen in the F2 pups. All differences observed reflected the normal biological variation in this strain of rats.
Gross pathological findings:
effects observed, non-treatment-related
Description (incidence and severity):
For a number of F2 pups, findings were detected at gross necropsy such as hemorrhagic thymus, small liver, empty stomach, dilated renal pelvis, small kidney and cystic dilatation of ovary. All pup necropsy findings occurred without relation to dosing. Furthermore, equal or similar findings can be found in the historical control data at comparable or even higher incidences. The number of affected pups per litter showing hemorrhagic thymus was statistically significantly increased in test group 13 (1000 mg/kg bw/d). However, this calculated incidence of 5.7% was clearly within the range of historical control data.
Histopathological findings:
not examined
Behaviour (functional findings):
not examined
Developmental immunotoxicity:
not examined
Key result
Dose descriptor:
NOAEL
Generation:
F2
Effect level:
1 000 mg/kg bw/day (nominal)
Based on:
test mat.
Sex:
male/female
Basis for effect level:
other: pre-and postnatal developmental toxicity
Key result
Critical effects observed:
no
Key result
Reproductive effects observed:
yes
Lowest effective dose / conc.:
1 000 mg/kg bw/day (nominal)
Treatment related:
yes
Relation to other toxic effects:
reproductive effects as a secondary non-specific consequence of other toxic effects
Dose response relationship:
yes
Relevant for humans:
not specified

Test substance stability:

The stability of test substance in rat diet was demonstrated for a period of 32 days at room temperature in a different batch of comparable quality, which was not used for the study. The homogeneity of the mixtures was verified. The concentration control analyses of the samples taken revealed that the values were within a range of 90-110% of the nominal concentration in all analyses at all time points, with the exception of one concentration in the feed of the high-dose group (88%).

Plasma concentrations of 2 -aminoethanol were below 3 mg/kg for all control animals, <3 - 4 mg/kg for the low dose animals, 8 - 11 mg/kg for the mid dose animals and 60 – 81 mg/kg for the high dose animals.

Toxicokinetic data of 2 -aminoethanol (calculated as 2 -aminoethanol hydrochloride) from this two-generation reproduction toxicity study show a dose dependency of the plasma levels of 2 -aminoethanol in the experimental animals and there with prove the bioavailability of 2 -aminoethanol hydrochloride in principle.

 

Under these conditions, no test substance-related findings from clinical examinations or gross and histopathology were observed, which indicate that the administration of the test compound via the diet adversely affected the fertility or reproductive performance of the F0 or F1 parental animals up to and including a nominal dose of 300 mg/kg bw/d. Estrous cycle data, mating behavior, conception, gestation, parturition, lactation and weaning as well as sperm parameters, sexual organ weights and gross and histopathological findings of these organs (including differential ovarian follicle counts in the F1 females) were comparable between the rats of all test groups.

At the high-dose level (1000 mg/kg bw/day), absolute and relative weights of epididymides and cauda epididymidis were decreased and, in the F0 generation only, the number of homogenization resistant caudal epididymal sperm was slightly, but significantly reduced. However, histomorphological correlates for these findings were missing.

 

In the high-dose F0 and F1 generation females (1000 mg/kg bw/day), decreased numbers of implants and increased resorption rates resulted in significantly smaller litters, giving evidence for an adverse effect of the test compound on fertility and/or reproductive performance at high doses. It has to be noted that a dose of 1000 mg/kg bw/day also caused beginning systemic toxicity in these females, as was indicated by reduced food consumption and/or body weight gain during gestation/lactation.

 

All data recorded during gestation and lactation in terms of embryo-/fetal and pup development gave no indications for any developmental toxicity in the F1 and F2 offspring up to a dose level of 1000 mg/kg bw/day. The test substance did not adversely influence pup viability, body weight, sex ratio and sexual maturation.

 

Thus, under the conditions of the present two-generation reproduction toxicity study, the NOAEL for fertility, reproductive performance and systemic toxicity in parental F0 and F1 Wistar rats is 300 mg/kg bw/day.

 

The NOAEL for pre-and postnatal developmental toxicity in their offspring is 1000 mg/kg bw/day.

Table 1 Mean test substance intake (mg/kg bw/day; minimum value / maximum value)

 

Test group 01
(100 mg/kg bw/day)

Test group 02
(300 mg/kg bw/day)

Test group 03
(1000 mg/kg bw/day)

F0 males

94.3 (72.4 / 102.5)

283.2 (218.4 / 309.4)

943.3 (716.7 / 1032.6)

F0 females (premating)

96.7 (80.5 / 100.7)

289.6 (241.2 / 304.9)

964.4 (792.4 / 1017.8)

F0 females
(F1 litter)
- gestation period
- lactation period*



103.5 (92.6 / 111.6)
99.2 (81.6 / 120.2)



315.2 (284.8 / 337.9)
306.7 (249.7 / 370.3)



1043.2 (989.4 / 1084.7)
866.0 (668.6 / 1053.9)

* = Days 1–14 p.p. only

Table 2 Absolute organ weights (P-generation)

Compared to the controls (= 100%), the following values (in %) were significantly changed (printed in bold):

 

Male animals

Female animals

Group

01

100 mg/kg bw/day

02

300 mg/kg bw/day

03

1000 mg/kg bw/day

01

100 mg/kg bw/day

02

300 mg/kg bw/day

03

1000 mg/kg bw/day

Brain

99%

100%

97%*

 

 

 

Cauda epididymis

99%

102%

88%**

 

 

 

Epididymides

100%

101%

92%**

 

 

 

Prostate

92%

99%

86%**

 

 

 

Spleen

 

 

 

105%*

107%

97%

 

*: p≤0.05; **: p≤0.01

 

All other mean absolute weight parameters did not show significant differences compared to the control groups.

 

The decrease of absolute weights of cauda epididymis, epididymides, and prostate in male top-dose animals (1000 mg/kg bw/day) were considered as treatment-related effects.

 

The decrease of brain weights in top-dose males (1000 mg/kg bw/day) as well as the increase of spleen weights in low-dose females (100 mg/kg bw/day) was considered as incidental and not treatment-related due to a missing dose-response relationship.

Table 3 Absolute organ weights (F1 generation)

Compared to the controls (= 100%), the following values (in %) were significantly changed (printed in bold):

 

 

Male animals

Female animals

Group

11

100 mg/kg bw/day

12

300 mg/kg bw/day

13

1000 mg/kg bw day

11

100 mg/kg bw/day

12

300 mg/kg bw/day

13

1000 mg/kg bw/day

Cauda epididymis

96%

99%

88%**

 

 

 

Epididymides

100%

101%

91%**

 

 

 

Kidneys

99%

106%*

111%**

103%

106%**

115%**

Spleen

99%

103%

92%*

 

 

 

Thyroid glands

106%

99%

109%*

110%

118%**

111%*

 

*: p≤0.05; **: p≤0.01

All other mean absolute weight parameters did not show significant differences compared to the control groups.

The decrease of absolute weights of cauda epididymis and epididymides in male top-dose animals (1000 mg/kg bw/day) were considered to be treatment-related.

 

The increase of absolute kidney weights of male and female animals in mid- (300 mg/kg bw/day) and top-dose (1000 mg/kg bw/day) groups, respectively, was statistically significant. Because no histomorphological correlate was detected, a treatment-related weight increase was less likely.

 

The decrease of spleen weights in top-dose males as well as the increase of thyroid glands in top-dose males and mid- and top-dose females, respectively, is considered incidental and not treatment-related due to a missing dose-response relationship.

Effect on fertility: via oral route
Endpoint conclusion:
adverse effect observed
Dose descriptor:
NOAEL
300 mg/kg bw/day
Study duration:
subchronic
Species:
rat
Quality of whole database:
GLP study according OECD TG 416 (read-across)
Effect on fertility: via inhalation route
Endpoint conclusion:
no study available
Effect on fertility: via dermal route
Endpoint conclusion:
no study available
Additional information

There are no reproductive toxicity studies available performed with 3 -Aminopropan-1 -ol. However, a oral two generation reproduction toxicity study has been performed with the analogue chemical 2 -Aminoethanol (MEA).

2 -Aminoethanol HCl was tested in an oral two generation reproduction toxicity study according to OECD TG 416 and GLP-conditions (ACC and CEFIC, 2009). The test substance was administered to groups of 25 male and 25 female healthy young Wistar rats (F0 parental generation) as a homogeneous addition to the food in different concentrations, which were adjusted regularly to obtain target dose levels of 0, 100, 300 and 1000 mg/kg bw/day. At least 75 days after the beginning of treatment, F0 animals were mated to produce a litter (F1 generation). Regarding general repeated dose toxicity, the dose level of 1000 mg/kg bw/day caused systemic toxicity in parental females, as was indicated by reduced food consumption and/or body weight gain during gestation and lactation. In the mid and high dose F1 animals the absolute and relative kidney weights were statistical significantly increased without histopathological correlate findings. In the high-dose F0 and F1 males the test substance administration led to a decrease of absolute and relative organ weights of cauda epididymidis and epididymides. Furthermore, prostate weight and the number of homogenization resistant caudal epididymal sperm was slightly, but significantly, decreased in the F0 males. These findings were considered to be treatment-related effects, but histomorphological correlates were missing. Further, no effect upon testes or testicular sperm count, and no effect upon mating performance were observed. Therefore, the NOAEL for reproductive toxicity for male rats were set at 1000 mg/kg bw/day. Females at the high dose level revealed decreased numbers of implants, increased resorption rates, and smaller litters associated with systemic toxicity. Based on these effects, the NOAEL for reproductive toxicity in female rats was set at 300 mg/kg bw/day.

Exposure based adaptation of information requirements:

According to REGULATION (EC) No 1907/2006, Annex VIII, IX and X, testing of toxicity to reproduction (section 8.7) may be omitted, if relevant human exposure can be excluded in accordance with Annex XI section 3. Furthermore, and in accordance with section 3.2 (b) of Annex XI (as amended by Regulation 134/2009), testing for toxicity to reproduction can be omitted when the substance is not incorporated in an article and the manufacturer can demonstrate and document for all relevant scenarios that throughout the life cycle strictly controlled as well as rigorously contained conditions as set out in Article 18(4)(a) to (f) (Regulation 1907/2006) apply.

Life-cycle stage(s) covered:

 

1.      Manufacture of substance (PROCs 1, 2, 3,)

2.      Formulation of preparations (PROC 1, 2, 3)

3.      Charging and discharging of substances and mixtures (PROC 8b, 9)

4.      Use as intermediate (PROC 1, 2, 3)

5.      Use in gas treatment (PROC 1, 2, 3)

6.      Use in laboratories (PROC 15)

 

Classification:

Acute Tox. 4                      H302: Harmful if swallowed.

Skin Corr. 1B                     H314: Causes severe skin burns and eye damage.

Eye Dam. 1                        H318: Causes serious eye damage.

 

Data profile:

3-Aminopropanol (3-AP, CAS 156-87-6) is harmful after single uptake and is corrosive to the skin as well as the eyes. Based on a bacterial reverse mutation assay, a sister-chromatid exchange (SCE) assay, anin vitromammalian cell gene mutation test (HPRT), and anin vitromammalian cell micronucleus test the test substance is not considered to induce gene mutations neither in the absence nor in the presence of a metabolic activation system.

 

Manufacture of substance and formulation of preparation:

3-Aminopropanol (3-AP, CAS 156-87-6) is manufactured in a continuous multi-product plant by reaction of ethylene cyanohydrin with hydrogen in the presence of ammonia and a solid catalyst.

The feedstocks ethylene cyanohydrin, stored in large tanks, and hydrogen, sourced from the site hydrogen grid, are fed into a trickle bed reactor which is filled with a catalyst. In addition, Ammonia is added. The hydrogenation reaction operates at elevated pressure and temperature, with recirculation of hydrogen and ammonia gas and back-mixing of the reaction medium.

After cooling down, the reaction mixture, rich in 3-AP, is separated in gas and liquid by a two-pressure expansion. The gas phase is partially returned to hydrogenation, while the remaining liquid is sent to a distillation tower where residual ammonia is distilled off under pressure and recovered to be re-used in the synthesis step. At the bottom of the tower, crude 3-AP is discharged and pumped to dedicated intermediate storage tanks. As a measure of quality assurance, the crude product is analyzed twice a day. For sampling, workers wear stringent personal protective equipment (PPE), such as substance appropriate gloves, appropriate skin coverage as well as suitable eye protection (protective goggles and face shield). Thus, exposure is considered to be controlled and negligible.

The purification of crude 3-AP is carried out in campaigns in a continuous multi-product distillation train. 3-AP is transferred via pipeline from the intermediate storage tanks to a series of distillation towers where low and middle boilers as well as heavies are safely separated from the product. The finished product, withdrawn as the top product of the purification tower, is analyzed every few hours and pumped to one of two dedicated check tanks. As before, for sampling tasks workers wear stringent personal protective equipment (PPE), such as substance appropriate gloves, appropriate skin coverage as well as suitable eye protection (protective goggles and face shield). Thus, exposure is considered to be controlled and negligible.

When filled, the check tanks are sampled for quality control. If the material passes the quality and sensory testing, it will be transferred to the final 3-AP storage tank where tank trucks and rail cars are loaded for delivery to internal and external customers. Loading takes place at a dedicated facility specifically designed and operated for the transfer of hazardous substances. In addition to the technical risk management measures in place, workers wear stringent PPE. Thus, exposure is considered to be controlled and negligible.

The production plants as well as all infrastructure as to steam, condensate, raw materials, products and wastes are designed to avoid open handling of materials and thus the exposure of operators, technicians and mechanics to 3-AP is controlled and negligible.

Both production lines and corresponding tank farms are well equipped with operational and monitoring devices to control and adjust process parameters (pressure, temperature, liquid level, flows, etc.). Safety instrumented systems are in place to prevent these parameters from reaching unsafe levels that could result in unacceptable risks to employees or the environment.

Product contamination due to product changeovers are obviated in both synthesis and distillation train by flushing all pieces of equipment with methanol and/or water depending on the solubility behavior of the previous product. The flushing media are sent via pipeline to incineration for disposal.

While producing 3-AP, only little waste water is generated which requires effluent treatment in the waste water treatment plant on site. Liquid waste streams resulting mainly from the distillation process are of organic nature and are collected in buffer tanks, until they are disposed of via the existing disposal systems for light and heavy boiling residues (pipeline and tank truck deliveries to residue incineration plant on site).

Exhaust piping from the synthesis and distillation train is connected to an incinerator of an adjacent production unit. To avoid air emissions of hazardous materials securely, the exhaust gas will be directed automatically to an emergency flare, should the incinerator fail.

Potential hazards for operators, technicians and mechanics, arising from any activities or tasks (e.g. sampling, loading/unloading of tank truck and rail cars, leak repair etc.) related to production assets are evaluated and documented in risk assessments and work permits. Safety procedures and exposure mitigation measures (e.g. personal protective equipment to wear) are in place.

 

Use as intermediate:

3-Aminopropanol (3-AP, CAS 156-87-6) is used as intermediate under strictly controlled conditions as a starting material for the synthesis of D-panthenol.Potential hazards for operators, technicians and mechanics, arising from any activities or tasks (e.g. sampling, loading/unloading of tank truck and rail cars, leak repair etc.) related to production assets are evaluated and documented in risk assessments and work permits. Safety procedures and exposure mitigation measures (e.g. personal protective equipment to wear) are in place.

 

Use in Gas Treatment and Charging and Discharging:

3-Aminopropanol (3-AP, CAS 156-87-6), in combination with other amines, is applied as an aqueous solution in closed-loop processes for capturing CO2from gas streams, mainly flue gas.

The gas stream containing CO2is introduced through an exhaust pipe into the purification plant. The exhaust gas in the exhaust pipe is introduced into a direct contact cooler where the exhaust gas is washed and humidified by counter-current flow to water. The cooled and humidified exhaust gas is then introduced into an absorber, where the exhaust gas is brought in counter-current flow to an aqueous absorbent solution (containing 3-AP and other amines) introduced through a lean amine pipe. Rich absorbent having absorbed CO2is collected at the bottom of the absorber and is withdrawn trough a rich absorbent pipe, whereas the CO2lean exhaust gas is released through a lean exhaust pipe after being washed in washing sections by means of water recycled through washing water cooling circuits. Because of extensive emission control systems and the relatively low volatility of 3-AP, the emission with treated flue gas will be very low and exposure to the public will be neglectable.

The rich absorbent is heated against the lean absorbent by means of a heat exchanger before being introduced into a regeneration column where the rich absorbent is stripped by counter-current flow to steam. The stripping steam is generated in a reboiler in which the lean absorbent collected at the bottom of the regeneration column is introduced through a lean absorbent withdrawal pipe.

Lean absorbent is withdrawn from the reboiler through the lean absorbent pipe and recycled into the absorber. Steam and CO2liberated from the absorbent in the regeneration column is washed in washing sections by counter-current flow to water recirculating in washing water cooling circuits, before being withdrawn through a CO2collection pipe. The CO2and steam are cooled in a condenser and condensed water is removed in a separator and recycled into the regeneration column through a recycling line. The partly dried CO2is withdrawn through a pipe for further treatment and downstream use.

The purification plant is equipped with sampling ports for gas and liquid, temperature and pressure probes and measurements of gas/liquid flow in all parts of the plant.

Waste products are incinerated, and waste water if any is routed to waste water treatment. Waste products are handled as hazardous waste by an approved waste handling company according to local regulations. Dedicated procedures are in place for all operating steps involving the substance handling, e.g. procedures for transfer of process inventory, draining of process units, clean-up of spillage, waste handling, etc.

Storage equipment such as the amine make-up tank for the process is sealed or nitrogen blanketed. The make-up tank could be charged a few times year from a road tanker/bulk transport with very limited exposure of workers due to the above described precautions. Accidental spills of 3-AP to the environment are avoided, as the purification plant is placed in a bunded area.

In view of the high degree of automation and closed nature of this process, exposure is limited to sampling procedures, cleaning and maintenance of equipment. Risk management measures are constantly applied by the highly trained and restricted personnel to minimize exposure.

 

Rigorous containment measures:

3-Aminopropanol (3-AP, CAS 156-87-6) is manufactured and used under strictly controlled conditions over the entire lifecycle. Exposure is limited to occasional sampling tasks for quality control, as well as to charging and discharging processes. Here, as well as during the handling for quality control analysis in the laboratory, risk management measures and stringent personal protective equipment are continuously applied. Transport, storage tanks, reactors, processing equipment, and feeds operate in fully closed systems.

  

Procedural and control technologies are used to minimize residual emissions/exposure as well as qualitative risk considerations:

Operational and technical conditions and measures affecting and controlling workers exposure, such as local exhaust ventilation as well as personal protective equipment, such as goggles, chemically resistant gloves, and respiratory protection where potential exposure may occur as reported in the CSR are followed (see chapters 9 & 10).

On the basis of the described process conditions, testing of 3-Aminopropan-1-ol in a reproduction toxicity (screening) study (OECD 421/422/415/416/443) was not performed since the criteria of exposure based adaptation of information requirements are met.

Effects on developmental toxicity

Description of key information

Based on the results of the available developmental toxicity studies with rats and rabbits (oral and dermal route of exposure, respectively), with the structural analogue 2 -Aminoethanol, 3 -Aminopropan-1-ol is not considered to be a developmental toxicant.

Link to relevant study records

Referenceopen allclose all

Endpoint:
developmental toxicity
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
guideline study
Qualifier:
according to guideline
Guideline:
OECD Guideline 414 (Prenatal Developmental Toxicity Study)
GLP compliance:
yes
Limit test:
no
Specific details on test material used for the study:
SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: Sample 25 (cont. production)
- Test substance No.: 91/351
Species:
rat
Strain:
Wistar
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Sexually mature, virgin Wistar rats (Chbb :THOM (SPF)) supplied by Karl THOMAE, Biberach an der Riss, Germany,
- Age at study initiation: 60 days
- Weight at study initiation: mean weight approx. 223.7 g
- Fasting period before study: none
- Housing: singly in type DK III stainless steel wire mesh cages supplied by Becker & Co., Castrop-Rauxel, Germany (floor area about 800 cm²) ;
- Diet: ground Kliba 343 feed rat/mouse/hamster supplied by Klingentalermuehle AG, Kaiseraugst, Switzerland; ad libitum
- Water: tap water; ad libitum
- Acclimation period: 5 days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 30-70
- Photoperiod (hrs dark / hrs light): 12/12

Route of administration:
oral: gavage
Vehicle:
water
Details on exposure:
PREPARATION OF DOSING SOLUTIONS:
Each day the test substance solutions were freshly prepared shortly before the test substance was administered. For the preparation of the solutions, an appropriate amount of the test substance was weighed in a volumetric flask and subsequently topped up with doubly distilled water and intensively shaken.

VEHICLE
- Amount of vehicle: 10 mL/ kg bw.
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
The homogeneity of the test substance was proven by visual inspection. The content of active ingredient was 99.4% before the beginning of the study. The re-analysis of the test substance proved its stability (content: 99.5%)
Details on mating procedure:
- Impregnation procedure: [cohoused]
- If cohoused:
- M/F ratio per cage: 1/1
- Verification of same strain and source of both sexes: yes
- Proof of pregnancy: sperm in vaginal smear referred to as day 0of pregnancy
Duration of treatment / exposure:
day 6 - 15 of gestation
Frequency of treatment:
daily, once per day
Duration of test:
up to day 21 of gestation
Dose / conc.:
40 mg/kg bw/day (actual dose received)
Dose / conc.:
120 mg/kg bw/day (actual dose received)
Dose / conc.:
450 mg/kg bw/day (actual dose received)
No. of animals per sex per dose:
40 dams per dosing group
Control animals:
yes, concurrent vehicle
Details on study design:
On day 0, the animals were assigned to the different test groups according to a randomization plan. The test substance was administered to the animals orally (by gavage) once a day during the period of major organogenesis (day 6 to day 15 p .c .) always at approx. the same time of day (in the morning). The animals of the control group were treated in the same way with the vehicle (doubly distilled water). The volume administered each day was 10 mL/kg body weight. The calculation of the volume administered was based on the individual body weight determined at the beginning of the administration period (day 6 p.c.). On day 20 p.c., the first 25 animals/group were sacrificed in a randomized order and examined macroscopically. The fetuses were dissected from the uterus and further investigated with different methods. The other animals (15/group) were allowed to litter and rear their pups up to day 21 p.p. (post partum). On day 21 post partum (p.p.) or one of the following days the relevant dams and pups were sacrificed and examined macroscopically.
Maternal examinations:
Clinical examinations
Food consumption
With the exception of day 0 p.c. (all animals) and days 0 p.p. and 21 p.p. (for animals with terminal
sacrifice on day 21 p.p. only), the consumption of food was determined on the same days as was body weight. Food consumption was not determined for the females without litter during the lactation period of the dams used in parallel.

Body weight data
All animals were weighed on days 0, 1, 3, 6, 8, 10, 13, 15, 17 and 20 p.c. Body weights of the animals with
terminal sacrifice on day 21 p.p. were additionally determined on the day of birth and on days 4, 7, 14 and
21 p.p. The body weight change of the animals was calculated from these results. Body weights of the animals without litter were not determined during the lactation period of the dams used in parallel.

Corrected body weight gain (net maternal body weight change)
Furthermore, the corrected body weight gain was calculated for all animals with terminal sacrifice on day 20 p.c. (terminal body weight on day 20 p.c. minus weight of the uterus before it was opened minus body
weight on day 6 p.c.).

Clinical symptoms
All animals were examined for clinical symptoms at least once a day, or more often when clinical signs of toxicity were elicited. The nesting, littering, and lactation behavior of the dams with terminal sacrifice day 21 p.p. was generally evaluated in the mornings in connection with the daily clinical inspection of the dams. Only if there were any special findings (e.g., animal could not litter, umbilical cord not cut), these specific findings were documented with the dam concerned.

The littering behavior of the relevant dams was also inspected on weekdays (except holidays) in the afternoons in addition to the evaluations in the mornings. These reevaluation were documented separately, but, as before, findings were only recorded with the dams concerned. Moreover, the duration of gestation, the number of live and dead pups at birth and litter size were recorded for the animals with terminal sacrifice on day 21 p.p. For these animals the fertility and the gestation indices were calculated according to the following formulae :

fertility index = (n pregnant animals/ n mated animals) x 100

gestation index = (n animals with litters/ n pregnant animals) x 100

The values listed in the Summary Tables are group means determined from the fertility/gestation indices of the individual animals.

Mortality
A check was made twice a day on working days or once a day (Saturday, Sunday or on public holidays).
Ovaries and uterine content:
Examinations of the dams at termination
Dams with terminal sacrifice on day 20 p.c.
On day 20 p.c., the dams were sacrificed in randomized order by cervical dislocation and the fetuses dissected from the uterus. After the dams had been sacrificed , they were necropsied and assessed by gross pathology. The uterus and the ovaries were removed and the following data were recorded :

Weight of uterus before it was opened
- Number of corpora lutea
- Number and distribution of implantation sites classified as :
• live fetuses
• dead implantations:
a) early resorptions (only decidual or placental tissues visible or according to Salewski from uteri from apparently non-pregnant animals and the empty uterus horn in the case of single-horn pregnancy)
b) late resorptions (embryonic or fetal tissue in addition to placental tissue visible)
c) dead fetuses (hypoxemic fetuses which did not breathe spontaneously after the uterus had been
opened)

Furthermore, calculations of conception rate and pre- and postimplantation losses were carried out:
- The conception rate (in %) was calculated according to the following formula :

conception rate = (number of pregnant animals/ number of fertilized animals) x 100

- The preimplantation loss (in % ) was calculated according to the following formula:

((number of corpora lutea - number of implantations)/number of corpora lutea) x 100

- The post implantation loss (in % ) was calculated from the following formula:

((number of implantations - number of live fetuses)/number of implantations) x 100

Dams with terminal sacrifice on day 21 p.p.
On day 21 post partum (p. p. ) the relevant dams were sacrificed by cervical dislocation. After the dams had been sacrificed, the following examinations were carried out:
- gross - pathological examination
- staining of uterus according to Salewski for determination of the number of implantations

Furthermore, calculations of conception rate and postimplantation loss were carried out:
- The conception rate (in %) was calculated according to the following formula :

conception rate = (number of pregnant animals/ number of fertilized animals) x 100

- The post implantation loss (in % ) was calculated from the following formula:

((number of implantations - number of live fetuses)/number of implantations) x 100
Fetal examinations:
Examination of the fetuses:
Examination of the fetuses after dissection from the uterus
At necropsy each fetus was weighed, sexed and examined macroscopically for any external findings. The sex was determined by observing the distance between the anus and the base of the genital tubercle and was later confirmed in all fetuses fixed in Bouin's solution by internal examination. If there were discrepancies between the "external" and the "internal" sex of a fetus, the fetus was finally sexed according to the appearance of its gonads. Furthermore, the viability of the fetuses and the condition of the placentae, the umbilical cords, the fetal membranes and fluids were examined. Individual placental weights were recorded. After these examinations, approximately one half of the fetuses per dam was placed in ethyl alcohol and the other half was placed in Bouin's solution for fixation and further evaluation.

Soft tissue examination of the fetuses
After fixation in Bouin's solution, approximately one half of the fetuses of the dams of all groups was examined for any findings in the organs according to the method of Barrow and Taylor with special attention being paid to the kidneys and the ureters. After the examination, these fetuses were discarded with the exception of the kidneys, which were placed into cassettes separately for each fetus and kept in 4% formaldehyde solution for possible further examination by light microscopy. Moreover, after fixation of the fetuses placed in ethyl alcohol for further evaluation of the fetal skeletons the organs of these fetuses were examined macroscopically. Thereafter, the kidneys of each fetus were placed into cassettes and kept in 4% formaldehyde solution for a possible further examination by light microscopy, while the other organs were discarded. Afterwards the carcasses of these fetuses were stained according to a modified method (Dawson) for the presentation of the skeletons.

Skeletal examination of the fetuses
After fixation in ethyl alcohol and examination of the organs, the skeletons of the fetuses were stained according to a modified method of Dawson. Thereafter, the skeletons of these fetuses were examined under a stereomicroscope. After these examinations the relevant fetuses were retained by litter.

Evaluation criteria for assessing skeletons and organs of the fetuses
In the present investigations the following terms (definitions) were used for describing a change:
- Malformations (concerning external, soft tissue and skeletal observations)
Rare and/or probably lethal changes were classified as malformations (e.g. exencephaly, atresia ani, hernia umbilicalis).

- Variations (concerning external, soft tissue and skeletal observations)
Changes which occur regularly also in control groups and have generally no adverse effect on survival were regarded as variations (e.g. dilated renal pelvis).

- Retardations (concerning skeletal observations only)
Delays in skeletal development compared with the norm at the time of the examination were considered to be retardations (e.g. sternebra(e) not ossified)

- Unclassified observations (concerning external and soft tissue observations, only)
External or soft tissue observations, which could not be classified as malformations or variations (e.g. blood coagulum around placenta).

Examination of the pubs:
Pup number and status at delivery
All pups derived from the females were examined as soon as possible on the day of birth to determine the total number of pups and the number of liveborn and stillborn members of each litter. Pups which died before the first determination of their status on the day of birth were designated as stillborn pups.

Pup viability / mortality
In general, a check was made for any dead or moribund pups twice daily on workdays (once in the morning and once in the afternoon) or as a rule, only in the morning on Saturdays, Sundays or public holidays. Dead pups were evaluated by the methods which will be described in detail before.
The number and percentage of dead pups on the day of birth (day 0) and of pups dying between days 1-4, 5-7, 8-14 and 15-21 of the lactation period were determined; however, pups which died accidentally were
not included in these calculations. The number of live pups/litter was calculated on the day of birth, and on
lactation days 4, 7, 14 and 21. Furthermore, viability and lactation indices were calculated according to the
following formulas :

Viability index (%) = (number of live pups on day 4 after birth/ number o f liveborn pups on the day of birth)
x 100

Lactation index (%) = (number of live pups on day 21 after birth/ number of live pup s on day 4 after birth)
x 100

Sex ratio
On the day of birth (day 0) the sex of the pups was determined by observing the distance between the anus and the base of the genital tubercle; normally, the anogenital distance is considerably greater in male than in female pups. During the following time the sex of the pups was assessed by the external appearance of the anogenital region and/or the mammary line of the animals and was finally confirmed at necropsy. The sex ratio was calculated for day 0 and day 21 after birth according to the following formula:

sex ratio = (number of live male or female pups on day 0/21 / number of live male and female pups on day 0/21) x 100

Pup body weight data
The pups were weighed on the day after birth (day 1 p.p.) and on days 4, 7, 14 and 21 after birth. Pups' body weight change was calculated from these results. The individual weights were always determined at about the same time of the day (in the morning). In the relevant summary tables pup body weights and pup body weight gains are listed for males, females and males + females.

Pup clinical observations
The pups were examined each day for clinical symptoms (including gross-morphological findings).

Pup necropsy observations
After sacrifice on day 21 p.p. or one of the following days (by means of CO2) or intercurrent death, the pups were examined externally, eviscerated and their organs were assessed macroscopically with special attention being paid to the urinary tract. After the macroscopic examination of the pups, the kidneys of each pup were placed into cassettes and fixed in 4% formaldehyde solution for a possible further examination by light microscopy. If there were notable findings or if abnormalities were found in the daily clinical observation of the animals after their delivery, the affected animals were, if it was deemed necessary, examined additionally using appropriate methods (e.g., skeletal staining according to modified Dawson's method and/or further processing of head according to Wilson's method. The stained skeletons were evaluated under a stereomicroscope or a magnifying glass. All pups without any notable findings or abnormalities were discarded after their macroscopic evaluation (with the exception of the kidneys (see above)).
Statistics:
Dunnett-Test was used for a simultaneous comparison of several dose groups with the control. The hypothesis of equal means was tested. This test was performed two-sided and was used for the statistical evaluation of food consumption, body weights and body weight change (females and pups), corrected body weight gain (net maternal body weight change), weight of the uterus before it was opened, number of corpora lutea, number of implantations, number of resorptions and number of live fetuses; proportion of preimplantation loss, postimplantation loss, resorptions and live fetuses in each litter; litter mean fetal body weight and litter mean placental weight, duration of gestation and number of pups delivered per litter. For the body weight and the body weight change of the pups the mean weight of each litter was used for the statistical analysis (statistical unit = litter).
Fisher' s Exact Test was used for a pairwise comparison of each dose group with the control for the hypothesis of equal proportions. This test was performed one - sided was used for statistical evaluation of the following parameters: female mortality, females pregnant at terminal sacrifice, number of litters with fetal findings, female fertility index, gestation index, females with liveborn, stillborn and with all stillborn pups, live birth index, pups stillborn, pups died, pups cannibalized, pups sacrificed moribund, viability index, lactation index, number of litters with affected pups at necropsy.
The Wilcoxon Test was used for a comparison of each dose group with the control for the hypothesis of equal medians. This test was performed one-sided and was used for the proportion of fetuses with malformations, variations, retardations and/or unclassified observations in each litter and for the proportion of affected pups per litter with necropsy observations. If the results of these tests were significant, labels (*for ≤ 5 0.05, ** for p ≤ 0.01) were printed in the summary tables.
Clinical signs:
effects observed, non-treatment-related
Description (incidence and severity):
No signs that might be attributed to the test substance administered were detected during gestation and lactation periods. During gestation, piloerection was recorded for one high dose animal on day 13. Without any dose-response relationship insufficient nesting activity was observed for several dams of all groups. During lactation one dam of the 40 mg/kg/day group was found dead on day 0 p.p. after an incomplete delivery. Moreover one dam of the 120 mg/kg/day group had a total litter loss on day 1 after birth. All of these findings are spontaneous in nature and cannot be attributed to the test substance administration.
Dermal irritation (if dermal study):
not examined
Mortality:
mortality observed, non-treatment-related
Description (incidence):
One dam of the 40 mg/kg/day group died intercurrently during delivery. Undelivered pups were found in the uterus.
Body weight and weight changes:
effects observed, treatment-related
Description (incidence and severity):
The mean maternal body weight of the 450 mg/kg/day group was statistically significantly lower than that of the control group on days 15, 17, and 20 of gestation. The high dose females gained statistically significantly less weight than the controls during the treatment-free interval of the gestation period (days 15-20) and on days 0, 4, 7, and 21 p.p. The results of the corrected body weight gain on gestation day 20 of all groups did not show any differences of biological significance.
Food consumption and compound intake (if feeding study):
effects observed, treatment-related
Description (incidence and severity):
The food consumption of the high dose animals (450 mg/kg/day) was statistically decreased within the first days of the treatment period (days 6-8 of gestation) and also after termination of the treatment on the last days of the gestation period (17-20 of gestation). During the beginning of the lactation period (days 0-4 p.p.) there was also a slight, but statistically significant reduction in the food consumption of the high dose animals.
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
effects observed, non-treatment-related
Description (incidence and severity):
One case of microphthalmia in the 450 mg/kg/day group was observed.
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Behaviour (functional findings):
not examined
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
no effects observed
Description (incidence and severity):
The uterus weights, which were determined for the animals with termination on day 20 of gestation only, were not influenced by the administration of the test substance. The differences between the groups is without biological relevance and do not show any dose-response relationship.
Gross pathological findings:
effects observed, non-treatment-related
Description (incidence and severity):
There were no substance-related observations at necropsy in any of the dams. Hydrometra (a spontaneous finding) was recorded for one female of the control group, for 2 females of the 40 mg/kg/day group, and 3 females of the 120 mg/kg/day group. These animals did not become pregnant. Edema of the lungs which has to be related to the termination of the rats was recorded for several dams of the control, low and intermediate groups without any relation to dosing. For the one low dose female that died intercurrently during parturition, undelivered pups were found in the uterus.
Neuropathological findings:
not examined
Histopathological findings: non-neoplastic:
not examined
Histopathological findings: neoplastic:
not examined
Number of abortions:
no effects observed
Description (incidence and severity):
No fetuses were aborted or delivered early in any of the groups.
Pre- and post-implantation loss:
no effects observed
Description (incidence and severity):
The mean % pre-implantation loss was 3.4, 6.8, 9.9 and 11.7 for the control, the 40 mg/kg/day, 120 mg/kg/day and the 450 mg/kg/day groups, respectively. The mean % post-implantation loss for the 20 gestational females was 10.3, 7.3, 7.0 and 6.3 for the control, the 40 mg/kg/day, 120 mg/kg/day and the 450 mg/kg/day groups, respectively. The mean % post-implantation loss for the 21 p.p. females was 5.7, 3.9, 9.7 and 7.3 for the control, the 40 mg/kg/day, 120 mg/kg/day and the 450 mg/kg/day groups, respectively. In the animals euthanized on day 20 of gestation, there were no-substance related and/or statistically significant differences in the values calculated for the pre- and postimplantation losses. The females euthanized on day 21 p.p. showed no substance-associated effects on the postimplantation loss.
Total litter losses by resorption:
no effects observed
Early or late resorptions:
no effects observed
Description (incidence and severity):
Mean early resorptions were 1.4, 0.9, 1.0 and 0.9 for the control, the 40 mg/kg/day, 120 mg/kg/day and the 450 mg/kg/day groups, respectively. Mean late resorptions were 0.2, 0.3, 0.1 and 0.0 for the control, the 40 mg/kg/day, 120 mg/kg/day and the 450 mg/kg/day groups, respectively. In the animals euthanized on day 20 of gestation, there were no-substance related and/or statistically significant differences in the number of resorptions.
Dead fetuses:
no effects observed
Description (incidence and severity):
The number of fetuses alive/dead were 293/0, 282/0, 263/0 and 311/0 for the control, the 40 mg/kg/day, 120 mg/kg/day and the 450 mg/kg/day groups, respectively.
Changes in number of pregnant:
no effects observed
Description (incidence and severity):
The conception rate varied between 85% (450 mg/kg/day group) and 75% (40 mg/kg/day group). The conception per dose level was 33 in the control group, 30 in the 40 mg/kg/day group, 33 in the 120 mg/kg/day group and 34 in the 450 mg/kg/day group. The number pregnant at caesarian-section was 21 in the control, 20 in the 40 and 120 mg/kg/day groups and 24 in the 450 mg/kg/day group. The females euthanized on day 21 p.p. showed no substance-associated effects on the fertility index which was 80%, 67%, 87% and 67% for the control, the 40 mg/kg/day, 120 mg/kg/day and the 450 mg/kg/day groups, respectively.
Details on maternal toxic effects:
Maternal toxic effects: yes
Monoethanolamine caused some signs of maternal toxicity when administered by gavage to pregnant Wistar rats from days 6 - 15 of gestation at the highest dose level tested, 450 mg/kg/day. Maternal toxicity was substantiated by reduced food consumption, lower mean body weights and impaired body weight gain. The oral administration of monoethanolamine at 450 mg/kg/day or doses below this had no influence on resorption rate, number of live fetuses or pups/dam, mean fetal weight or pup body weights.
Key result
Dose descriptor:
NOAEL
Effect level:
120 mg/kg bw/day
Based on:
test mat.
Basis for effect level:
body weight and weight gain
food consumption and compound intake
Key result
Abnormalities:
no effects observed
Fetal body weight changes:
effects observed, non-treatment-related
Description (incidence and severity):
The mean fetal body weights were not influenced by the test substance administration.
Without any clear relation to dosing, pup weights were occasionally statistically significantly lower in the substance-treated groups than in the respective control values. On day 21 p.p. control and high dose pup weights were substantially similar, whereas the mean pup body weights of the 40 and 120 mg/kg/day group were still slightly, but not significantly lower than the control values. On days 1-4 p.p. pup body weight gains were also statistically significantly lower in the substance-treated groups, again without a clear dose-response relationship. Because treatment of the dams took place only until day 15 of gestation and because of no clear dose-response relationship, it seems very unlikely that the differences in pup body weight/body weight gain are substance-related.
Reduction in number of live offspring:
no effects observed
Description (incidence and severity):
Of the females euthanized on day 21 p.p. the number of females with liveborn was 12, 10, 13, and 10 and the number of pups delivered was 165, 132, 170, and 125 for the control, the 40 mg/kg/day, 120 mg/kg/day and the 450 mg/kg/day groups, respectively.
Changes in sex ratio:
no effects observed
Description (incidence and severity):
The sex distribution and sex ratios of live pups on the day of birth and on day 21 p.p. did not show any substantial difference between controls and treated test groups.
Changes in litter size and weights:
no effects observed
Description (incidence and severity):
The litter size was not influenced by the test substance administration.
Changes in postnatal survival:
no effects observed
Description (incidence and severity):
The mean number of delivered pups/dam was not influenced by the administration of test substance. There were no substantial biological relevant differences concerning pup viability/ mortality in any of the groups. Viability and lactation indices were unaffected.
External malformations:
effects observed, non-treatment-related
Description (incidence and severity):
The only external malformation which was found was an anasarca in one high-dose fetus. This malformation is also present at a low incidence in the historical control data. The external exami nation of the fetuses revealed no variations in any group.
Skeletal malformations:
effects observed, non-treatment-related
Description (incidence and severity):
The only skeletal malformations which occurred were related to the thoracic part of the vertebral column (thoracic vertebral body/bodies dumbbell-shaped (asymmetrical) or bipartite (asymmetrical)). One or both of these malformations were found in a few fetuses of each test group including the controls without any biological relevant differences. The variations elicited were related to the ribs (shortened 13th rib(s), accessory 14th rib(s), rudimentary cervical rib(s), and the sternum (sternebra(e) of irregular shape or bipartite). These variations had no clear dose-response relationship, can be found in a similar frequency in historical control data, and/or the differences between groups are without biological significance. In all groups signs of retardations (incomplete or missing ossification of vertebral bodies/arches and the sternebra(e)) were found. The differences between the groups, however, are not associated with the test substance administration. All of the skeletal retardations are to be found at a comparable frequency in the historical control data and most often a clear dose-response relationship is not present. The only statistically significant difference, an increased rate of total variations in the 120 mg/kg/day group, is without biological relevance because it shows no dose-dependence.
Visceral malformations:
effects observed, non-treatment-related
Description (incidence and severity):
In all groups, including the control, some soft tissue malformations were found. These malformations were related to the eyes (microphthalmia), the heart (dilatation of the right or both ventricles; dextrocardia), the lung (uni-lobular) or the kidneys (hyper-/hypoplasia) and did not show any relation to dose. Two soft tissue variations, which were related to the urinary tract (dilated renal pelvis; hydroureter) occurred in all groups without any dose-response relationship and were fully within the historical control range. One unclassified observation (bloody inhibition of the kidneys) was recorded for 3 control and one high dose fetus.
Details on embryotoxic / teratogenic effects:
Embryotoxic / teratogenic effects: no effects
No signs of developmental toxicity occurred up to and including the highest dose level (450 mg/kg/day), especially no substance-induced teratogenic effects were observed neither in the fetuses nor in the pups. Furthermore, there were no indications for any substance-related growth retardations. The urinary tract of the rat fetuses/pups did not show any treatment-related findings. Dilated renal pelvis and/or hydroureter were found in a considerable, but according to historical control data, not unexpected high number of fetuses of all groups including the controls without any relation to dosing, but did not occur at an increased rate in the pups of the substance-related groups. All skeletal malformations, variations, or retardations which occurred did not show a clear dose-response relationship, can be found at comparable or even higher rates within the historical control and/or the differences between the groups are without biological significance.
Key result
Dose descriptor:
NOAEL
Effect level:
>= 450 mg/kg bw/day
Based on:
test mat.
Sex:
male/female
Basis for effect level:
other: teratogenicity
Key result
Abnormalities:
no effects observed
Key result
Developmental effects observed:
no
Endpoint:
developmental toxicity
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
guideline study with acceptable restrictions
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 414 (Prenatal Developmental Toxicity Study)
Principles of method if other than guideline:
Pregnant New Zealand White rabbits were exposed dermally to 0, 10, 25, and 75 mg/kg/day of monoethanolamine (MEA) for approximately 6 hr/day on Days 6 through 18 of gestation.
GLP compliance:
not specified
Limit test:
no
Species:
rabbit
Strain:
New Zealand White
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Hazelton Research Products, Inc. (Denver, PA), USA
- Weight at study initiation: 3 .0-4 .0 kg)
- Fasting period before study: none
- Housing: in wire-bottom cages
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 2 weeks

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20
- Humidity (%): 40-60
- Photoperiod (hrs dark / hrs light): 12/12



Route of administration:
dermal
Vehicle:
water
Details on exposure:
TEST SITE
- Area of exposure: shaved skin of the back
- Type of wrap if used: sterile gauze held in place by Lycra-Spandex jacket

REMOVAL OF TEST SUBSTANCE
- Washing: water-dampened towel was used to wipe remaining test material off
- Time after start of exposure: 6 hours

TEST MATERIAL
- Amount(s) applied: 2 mL/kg
- Constant volume or concentration used: no
Analytical verification of doses or concentrations:
not specified
Details on mating procedure:
- Impregnation procedure: [cohoused]
- If cohoused:
- M/F ratio per cage: 2/1
- Length of cohabitation: over night
- Verification of same strain and source of both sexes: yes
- Proof of pregnancy: copulation referred to as day 0 of pregnancy
Duration of treatment / exposure:
day 6 - 18 of gestation
Frequency of treatment:
6 hours/day, daily
Duration of test:
up to day 29 of gestation
Dose / conc.:
10 mg/kg bw/day
Dose / conc.:
25 mg/kg bw/day
Dose / conc.:
75 mg/kg bw/day
No. of animals per sex per dose:
15 dams/group
Control animals:
yes, concurrent vehicle
Details on study design:
- Dose selection rationale: Dose levels selected for these studies were chosen based upon the results of dermal range-finding and teratology probe studies conducted in rabbits
Maternal examinations:
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily

DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily

BODY WEIGHT: Yes
- Time schedule for examinations: gestation days 0, 3, 6, 9, 12, 15, 18, 24 and 21

FOOD CONSUMPTION: Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes

WATER CONSUMPTION: No

POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 29
- Organs examined: weights of liver, kidneys

OTHER: Blood analysis prior to caesarian section; skin irritation was evaluated once daily during the postdosing period
Ovaries and uterine content:
The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: Uteri with no visible implantations were stained with a 10% sulfide solution.
Fetal examinations:
- External examinations: Yes: [all per litter]
- Soft tissue examinations: Yes: [all per litter]
- Skeletal examinations: Yes: [half per litter]
- Head examinations: Yes: [half per litter ]


All fetuses were weighed and examined for evidence of external alterations and palate closure. All of the rabbit fetuses in each litter were examined for visceral alterations (Staples,1974). The sex of all live fetuses was determined. The heads of one half of the rabbit fetuses not selected for skeletal examination were removed, placed in Bouin's solution, and subsequently sectioned and examined for craniofacial defects (Wilson, 1 965 ; Van Julsingha and B ennet, 1977). All fetuses were eviscerated and stained with alizarin red-S ( Dawson, 1926; Crary, 1962). Skeletal examinations were conducted only on the rat fetuses not selected for Bouin's examination.
Statistics:
Continuous data were evaluated for homogeneity of variance using Levene's test (Levene, 1960). Based upon the outcome of this test, a parametric or nonparametric analysis of variance (ANOVA) was performed. If the ANOVA was significant, analysis by Dunnett's test (Steel and Torrie, 1960), the Wilcoxen Rank-Sum test with Bonferroni's correction (Miller, 1966), or a pooled t test was performed as appropriate. The level of statistical significance was set a priori at a = 0.05. Nonparametric data were compared using Fischer's exact probability test (Siegel, 1956).
Clinical signs:
no effects observed
Dermal irritation (if dermal study):
effects observed, treatment-related
Description (incidence and severity):
Rabbits administered 75 mg/kg/day of MEA exhibited severe skin irritation (erythema, edema, ecchymosis, necrosis, exfoliation, and crusting) at the site of exposure. Subsequent to the dosing period, exfoliation, crusting, and areas of necrosis persisted. The skin of the majority of these rabbits began to heal as evidenced by scab formation late in the gestation period. Crusting, transient erythema, and edema were noted in a few rabbits administered 25 mg MEA/kg/day. No significant dermal irritation or lesions were observed among rabbits administered 10 mg MEA/kg/day.
Mortality:
no mortality observed
Body weight and weight changes:
no effects observed
Description (incidence and severity):
No statistically identified changes were observed in body weight and body weight gain.
Food consumption and compound intake (if feeding study):
no effects observed
Description (incidence and severity):
There were no consistent treatment-related effects on gestational food consumption. Statistically significant reductions in food consumption for Days 25-26 and 18-29 were not considered to be a direct effect of treatment due to the magnitude of the reductions and the fact that the reductions occurred after completion of the treatment period.
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
no effects observed
Description (incidence and severity):
There were no treatment-related effects on the numbers of leukocytes, erythrocytes, or platelets. Mean values for hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration were equivalent across groups. Differential leukocyte evaluations also indicated no treatment-related effects.
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Behaviour (functional findings):
not examined
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
no effects observed
Description (incidence and severity):
There were no effects of treatment on gravid uterine weight, or liver and kidney weights.
Gross pathological findings:
no effects observed
Description (incidence and severity):
There were no effects of treatment on terminal body weight, corrected body weight, corrected weight change. Findings listed for treated skin were consistent with clinical observations skin irritation scores for the 75 mg/kg/day group. There were no other pertinent necropsy findings.
Neuropathological findings:
not examined
Histopathological findings: non-neoplastic:
not examined
Histopathological findings: neoplastic:
not examined
Number of abortions:
no effects observed
Pre- and post-implantation loss:
no effects observed
Description (incidence and severity):
No treatment-related effects were observed on reproductive parameters including the number of implantations and resorptions. The reduced percent preimplantation loss at 75 mg/kg/day was considered to be spurious due to the lack of a dose-response relationship.
Total litter losses by resorption:
no effects observed
Description (incidence and severity):
No treatment-related effects were observed on reproductive parameters including the number of implantations and resorptions.
Early or late resorptions:
no effects observed
Dead fetuses:
no effects observed
Description (incidence and severity):
No treatment-related effects were observed on reproductive parameters including the number of dead fetuses.
Changes in pregnancy duration:
no effects observed
Description (incidence and severity):
No treatment-related effects were observed on preganacy duration.
Changes in number of pregnant:
no effects observed
Description (incidence and severity):
No treatment-related effects were observed on reproductive parameters including pregnancy rate.
Other effects:
no effects observed
Description (incidence and severity):
No treatment-related effects were observed on the number of corpora lutea.
Details on maternal toxic effects:
Maternal toxic effects: no effects
Rabbits administered 75 mg/kg/day of MEA exhibited severe skin irritation (erythema, edema, ecchymosis, necrosis, exfoliation, and crusting) at the site of exposure. Subsequent to the dosing period, exfoliation, crusting, and areas of necrosis persisted. The skin of the majority of these rabbits began to heal as evidenced by scab formation late in the gestation period. Crusting, transient erythema, and edema were noted in a few rabbits administered 25 mg MEA/kg/day. No significant dermal irritation or lesions were observed among rabbits administered 10 mg MEA/kg/day.

No females died, aborted, delivered early, or were removed from the test during the study. There were also no significant treatment-related effects observed on feed consumption, hematologic parameters, or kidney and liver weights of MEA-exposed rabbits at any dose level tested.

No statistically identified changes were observed in body weight and body weight gain, the average body weight gain of high-dose rabbits over the course of gestation was decreased when compared to that of the control and other dose groups, mainly due to weight loss or very little weight gain during the treatment period.
Key result
Dose descriptor:
NOAEL
Effect level:
10 mg/kg bw/day
Based on:
test mat.
Basis for effect level:
dermal irritation
Key result
Abnormalities:
no effects observed
Fetal body weight changes:
no effects observed
Description (incidence and severity):
There were no treatment-related effects on fetal body weights (all fetuses, male or female).
Reduction in number of live offspring:
no effects observed
Description (incidence and severity):
No treatment-related effects were observed on litter size.
Changes in sex ratio:
no effects observed
Description (incidence and severity):
There were no significant effects of treatment on sex ratio.
Changes in litter size and weights:
no effects observed
Changes in postnatal survival:
no effects observed
Description (incidence and severity):
There were no significant effects of treatment on the percentages of live fetuses.
External malformations:
effects observed, non-treatment-related
Skeletal malformations:
effects observed, non-treatment-related
Description (incidence and severity):
Among control litters the following types of malformations were noted: extra lumbar centrum and arches. Malformations observed in litters from rabbits given 10 mg/kg/day included misaligned or fused thoracic centra, extra lumbar centrum and arches, and fused ribs. Malformations observed in fetuses from the 75 mg/kg/day dose group litters included the following: diagonally displaced thoracic centra, missing thoracic arch, and a single missing rib.

Visceral malformations:
effects observed, non-treatment-related
Description (incidence and severity):
Among control litters the following types of malformations were noted: ventricular septal defect, common opening at entry of the vessels of the heart, missing lung lobe and a missing gall bladder. Malformations observed in litters from rabbits given 10 mg/kg/day included dilated lateral cerebral ventricle with tissue depression, missing lung lobe and a missing gallbladder. Malformations noted at 25 mg/kg/day included dilated lateral cerebral ventricle with tissue depression and missing lung lobe. Malformations observed in fetuses from the 75 mg/kg/day dose group litters included the following: dilated lateral cerebral ventricle with tissue depression and a missing lung lobe.
Key result
Dose descriptor:
NOAEL
Effect level:
> 75 mg/kg bw/day (actual dose received)
Based on:
test mat.
Basis for effect level:
other: no treatment related effects at highest dose tested
Key result
Abnormalities:
no effects observed
Key result
Developmental effects observed:
no
Endpoint:
developmental toxicity
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
comparable to guideline study with acceptable restrictions
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 414 (Prenatal Developmental Toxicity Study)
Principles of method if other than guideline:
Pregnant Sprague-Dawley rats were exposed dermally to 0, 10, 25, 75 and 225 mg/kg/day of monoethanolamine (MEA) for approximately 6 hr/day on Days 6 through 15 of gestation.
GLP compliance:
not specified
Limit test:
no
Species:
rat
Strain:
Sprague-Dawley
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Charles River Breeding Laboratories, Inc. (Kingston, NY), USA
- Age at study initiation:
- Weight at study initiation: 250-300 g)
- Housing: in wire-bottom cages
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 2 weeks

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22
- Humidity (%): 40-60
Route of administration:
dermal
Vehicle:
water
Details on exposure:
TEST SITE
- Area of exposure: shaved skin of the back
- Type of wrap if used: absorbant gauze pad followed by nonabsorbant cotton; an elastic bandage was wrapped securely around the animal to hold the patch in place and to prevent accidental ingestion of the test material via grooming during the exposure.

REMOVAL OF TEST SUBSTANCE
- Washing: water-dampened towel was used to wipe remaining test material off
- Time after start of exposure: 6 hours

TEST MATERIAL
- Amount(s) applied: 1 mL/kg
- Constant volume or concentration used: no
Details on mating procedure:
- Impregnation procedure: [cohoused]
- If cohoused:
- M/F ratio per cage: 1/1
- Length of cohabitation: over night
- Verification of same strain and source of both sexes: yes
- Proof of pregnancy: sperm in vaginal smear referred to as day 0 of pregnancy
Duration of treatment / exposure:
day 6 - 15 of gestation
Frequency of treatment:
6 hours/day, daily
Duration of test:
up to day 21 of gestation
Dose / conc.:
10 mg/kg bw/day
Dose / conc.:
25 mg/kg bw/day
Dose / conc.:
75 mg/kg bw/day
Dose / conc.:
225 mg/kg bw/day
No. of animals per sex per dose:
30-45 rats
Control animals:
yes, concurrent vehicle
Details on study design:
- Dose selection rationale: Dose levels selected for these studies were chosen based upon the results of dermal range-finding and teratology probe studies conducted in rats
Maternal examinations:
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily

DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily

BODY WEIGHT: Yes
- Time schedule for examinations: gestation days 0, 3, 6-16, and 21

FOOD CONSUMPTION: Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes

WATER CONSUMPTION: Yes

POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 21
- Organs examined: weights of liver, kidneys

Ovaries and uterine content:
The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: Uteri with no visible implantations were stained with a 10% sulfide solution.
Fetal examinations:
- External examinations: Yes: [all per litter]
- Soft tissue examinations: Yes: [half per litter]
- Skeletal examinations: Yes: [half per litter]
- Head examinations: Yes: [half per litter ]


All fetuses were weighed and examined for evidence of external alterations and palate closure. At least one-half of the rat fetuses in each litter were examined for visceral alterations (Staples,1974). The sex of all live fetuses was determined. The heads of rat fetuses not selected for skeletal examination were removed, placed in Bouin's solution, and subsequently sectioned and examined for craniofacial defects (Wilson, 1965; Van Julsingha and Bennet, 1977). All fetuses were eviscerated and stained with alizarin red-S ( Dawson, 1926; Crary, 1962). Skeletal examinations were conducted only on the rat fetuses not selected for Bouin's examination.
Statistics:
Continuous data were evaluated for homogeneity of variance using Bartlett's test (Winer, 1971). Based upon the outcome of these tests, a parametric or nonparametric analysis of variance (ANOVA) was performed. If the ANOVA was significant, analysis by Dunnett's test (Steel and Torrie, 1960), the Wilcoxen Rank-Sum test with Bonferroni's correction (Miller, 1966), or a pooled t test was performed as appropriate. The level of statistical significance was set a priori at a = 0.05. Nonparaznetric data were statistically treated using the Kruskal-Wallis test followed by the Mann-Whitney U test (Sokal and Rohlf, 1969), when appropriate. Incidence data for rats were analyzed using the Wilcoxon test as modified by Haseman and Hoel (1974). Fetal sex ratios were analyzed using a binomial distribution test (Steel and Torrie, 1960).
Clinical signs:
no effects observed
Dermal irritation (if dermal study):
effects observed, treatment-related
Description (incidence and severity):
Rats administered 225 mg MEA/kg/day exhibited a treatment-related increased incidence of skin irritation at the site of exposure. In general, the dermal irritation followed a progression, beginning with erythema and leading to necrosis, scabs, and scar formation. No significant dermal irritation or lesions were observed among rats administered lower doses of MEA.
Mortality:
no mortality observed
Body weight and weight changes:
effects observed, treatment-related
Description (incidence and severity):
During the exposure period the body weight gain of rats given 225 mg MEA/kg/day was significantly decreased.
Food consumption and compound intake (if feeding study):
no effects observed
Description (incidence and severity):
No significant differences were observed in the feed consumption of exposed rats relative to controls.
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
no effects observed
Description (incidence and severity):
No significant differences were observed in water consumption of exposed rats relative to controls.
Ophthalmological findings:
effects observed, non-treatment-related
Description (incidence and severity):
A case of microphthalmia observed in the control group.
Haematological findings:
no effects observed
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Behaviour (functional findings):
no effects observed
Immunological findings:
no effects observed
Organ weight findings including organ / body weight ratios:
no effects observed
Description (incidence and severity):
No effects on liver or kidney weights were observed at any dose level.
Gross pathological findings:
no effects observed
Description (incidence and severity):
There were no postmortem treatment-related effects observed in any dose group.
Neuropathological findings:
not examined
Histopathological findings: non-neoplastic:
not examined
Histopathological findings: neoplastic:
not examined
Number of abortions:
no effects observed
Pre- and post-implantation loss:
no effects observed
Description (incidence and severity):
There were no differences in the number of implantations.
Total litter losses by resorption:
no effects observed
Description (incidence and severity):
There were no differences in resorptions among any of the dose groups when compared to controls.
Early or late resorptions:
no effects observed
Description (incidence and severity):
There were no differences in resorptions among any of the dose groups when compared to controls.
Dead fetuses:
no effects observed
Description (incidence and severity):
There were no differences in number of dead fetuses among any of the dose groups when compared to controls.
Changes in pregnancy duration:
no effects observed
Changes in number of pregnant:
no effects observed
Description (incidence and severity):
There were no differences in pregnancy rate among any of the dose groups when compared to controls.
Other effects:
no effects observed
Description (incidence and severity):
There were no differences in number of corpora lutea mong any of the dose groups when compared to controls.
Details on maternal toxic effects:
Maternal toxic effects: yes
Rats administered 225 mg MEA/kg/day exhibited a treatment-related increased incidence of skin irritation at the site of exposure. In general, the dermal irritation followed a progression, beginning with erythema and leading to necrosis, scabs, and scar formation. No significant dermal irritation or lesions were observed among rats administered lower doses of MEA.

There were no postmortem treatment-related effects observed in any dose group. No significant differences were observed in the feed or water consumption of MEA exposed rats relative to controls.

The body weight gain of rats given 225 mg MEA/kg/day was significantly decreased during the exposure period. No effect on weight gain was observed in dams treated with lower levels of MEA.No effects on liver or kidney weights were observed at any dose level.
Key result
Dose descriptor:
NOAEL
Effect level:
75 mg/kg bw/day
Based on:
test mat.
Basis for effect level:
body weight and weight gain
dermal irritation
Abnormalities:
no effects observed
Fetal body weight changes:
no effects observed
Description (incidence and severity):
There were no differences in fetal body weight, or gravid uterine weight among any of the dose groups when compared to controls.
Reduction in number of live offspring:
no effects observed
Changes in sex ratio:
no effects observed
Description (incidence and severity):
There were no differences in fetal sex ratio among any of the dose groups when compared to controls.
Changes in litter size and weights:
no effects observed
Description (incidence and severity):
There were no differences in litter size among any of the dose groups when compared to controls.
Changes in postnatal survival:
not examined
External malformations:
effects observed, non-treatment-related
Skeletal malformations:
effects observed, non-treatment-related
Description (incidence and severity):
Malformations observed in the control and 25 mg MEA/kg/day dose group included an extra cervical rib.
Visceral malformations:
effects observed, non-treatment-related
Description (incidence and severity):
Among controls, the following types of malformations were observed: microphthalmia, retroesophageal right subclavian artery. Malformations observed in the 25 mg MEA/kg/day dose group included retroesophageal right subclavian artery. A single fetus was malformed in the 75 mg MEA/kg/day dose group. This fetus had multiple craniofacial malformations consisting of micrognathia, cleft lip and soft palate, and aglossia.
Key result
Dose descriptor:
NOAEL
Effect level:
>= 225 mg/kg bw/day
Based on:
test mat.
Basis for effect level:
other: developmental toxicity
Key result
Abnormalities:
no effects observed
Key result
Developmental effects observed:
no
Effect on developmental toxicity: via oral route
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
NOAEL
450 mg/kg bw/day
Study duration:
subacute
Species:
rat
Quality of whole database:
GLP study according OECD TG 414 (read-across)
Effect on developmental toxicity: via inhalation route
Endpoint conclusion:
no study available
Effect on developmental toxicity: via dermal route
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
NOAEL
225 mg/kg bw/day
Species:
rat
Quality of whole database:
GLP study similar to OECD TG 414 (read-across)
Additional information

There are no reliable developmental toxicity studies available performed with 3 -Aminopropan-1 -ol. However, two developmental toxicity studies have been performed with the analogue chemical 2 -Aminoethanol (MEA).

In a GLP-compliant prenatal developmental toxicity study with rats, performed according to OECD TG 414 (BASF SE, 1994; Hellwig and Liberacki, 1997) pregnant Wistar rats were exposed to MEA by gavage at dose levels 0, 40, 120, 450 mg/kg bw/day on days 6 - 15 of gestation. Signs of maternal toxicity were observed at the highest dose, manifested as reduced food consumption, lower mean body weights and impaired body weight gain. No reproductive and developmental toxicity parameters were affected. The NOAEL for developmental effects was thus established to correspond to 450 mg/kg bw/day; the NOAEL for maternal toxicity was 120 mg/kg bw/day.

In another comparable to guideline prenatal developmental toxicity study (Liberacki et al., 1996) rats and rabbits were exposed to the test substance dermally. Pregnant Sprague-Dawley rats were exposed dermally to 0, 10, 25, 75 and 225 mg/kg bw/day of 2 -Aminoethanol. Rats administered 225 mg MEA/kg bw/day exhibited a treatment-related increased incidence of skin irritation and the body weight gain was significantly decreased during the exposure period. Despite maternal effects observed among dams in the high dose group, reproductive and developmental toxicity parameters among exposed rats were unaffected at all dose levels. The NOAEL for maternal toxicity was set at 75 mg/kg bw/day and the NOAEL for developmental toxicity was set at the highest dose level of 225 mg/kg bw/day.

In the rabbit study exposure was via the dermal route to 0, 10, 25, and 75 mg/kg/day of MEA. The rabbits in the mid and high dose group exhibited signs of skin irritation, severe at the highest dose level. No treatment-related effects were observed on reproductive and developmental toxicity parameters. The NOAEL for maternal toxicity (local) was set at 10 mg/kg bw/day and the NOAEL for developmental toxicity was set at the highest dose level of 75 mg/kg bw/day.

Exposure based adaptation of information requirements:

According to REGULATION (EC) No 1907/2006, Annex VIII, IX and X, testing of toxicity to reproduction (section 8.7) may be omitted, if relevant human exposure can be excluded in accordance with Annex XI section 3. Furthermore, and in accordance with section 3.2 (b) of Annex XI (as amended by Regulation 134/2009), testing for toxicity to reproduction can be omitted when the substance is not incorporated in an article and the manufacturer can demonstrate and document for all relevant scenarios that throughout the life cycle strictly controlled as well as rigorously contained conditions as set out in Article 18(4)(a) to (f) (Regulation 1907/2006) apply.

Life-cycle stage(s) covered:

 

1.      Manufacture of substance (PROCs 1, 2, 3,)

2.      Formulation of preparations (PROC 1, 2, 3)

3.      Charging and discharging of substances and mixtures (PROC 8b, 9)

4.      Use as intermediate (PROC 1, 2, 3)

5.      Use in gas treatment (PROC 1, 2, 3)

6.      Use in laboratories (PROC 15)

 

Classification:

Acute Tox. 4                      H302: Harmful if swallowed.

Skin Corr. 1B                     H314: Causes severe skin burns and eye damage.

Eye Dam. 1                        H318: Causes serious eye damage.

 

Data profile:

3-Aminopropanol (3-AP, CAS 156-87-6) is harmful after single uptake and is corrosive to the skin as well as the eyes. Based on a bacterial reverse mutation assay, a sister-chromatid exchange (SCE) assay, anin vitromammalian cell gene mutation test (HPRT), and anin vitromammalian cell micronucleus test the test substance is not considered to induce gene mutations neither in the absence nor in the presence of a metabolic activation system.

 

Manufacture of substance and formulation of preparation:

3-Aminopropanol (3-AP, CAS 156-87-6) is manufactured in a continuous multi-product plant by reaction of ethylene cyanohydrin with hydrogen in the presence of ammonia and a solid catalyst.

The feedstocks ethylene cyanohydrin, stored in large tanks, and hydrogen, sourced from the site hydrogen grid, are fed into a trickle bed reactor which is filled with a catalyst. In addition, Ammonia is added. The hydrogenation reaction operates at elevated pressure and temperature, with recirculation of hydrogen and ammonia gas and back-mixing of the reaction medium.

After cooling down, the reaction mixture, rich in 3-AP, is separated in gas and liquid by a two-pressure expansion. The gas phase is partially returned to hydrogenation, while the remaining liquid is sent to a distillation tower where residual ammonia is distilled off under pressure and recovered to be re-used in the synthesis step. At the bottom of the tower, crude 3-AP is discharged and pumped to dedicated intermediate storage tanks. As a measure of quality assurance, the crude product is analyzed twice a day. For sampling, workers wear stringent personal protective equipment (PPE), such as substance appropriate gloves, appropriate skin coverage as well as suitable eye protection (protective goggles and face shield). Thus, exposure is considered to be controlled and negligible.

The purification of crude 3-AP is carried out in campaigns in a continuous multi-product distillation train. 3-AP is transferred via pipeline from the intermediate storage tanks to a series of distillation towers where low and middle boilers as well as heavies are safely separated from the product. The finished product, withdrawn as the top product of the purification tower, is analyzed every few hours and pumped to one of two dedicated check tanks. As before, for sampling tasks workers wear stringent personal protective equipment (PPE), such as substance appropriate gloves, appropriate skin coverage as well as suitable eye protection (protective goggles and face shield). Thus, exposure is considered to be controlled and negligible.

When filled, the check tanks are sampled for quality control. If the material passes the quality and sensory testing, it will be transferred to the final 3-AP storage tank where tank trucks and rail cars are loaded for delivery to internal and external customers. Loading takes place at a dedicated facility specifically designed and operated for the transfer of hazardous substances. In addition to the technical risk management measures in place, workers wear stringent PPE. Thus, exposure is considered to be controlled and negligible.

The production plants as well as all infrastructure as to steam, condensate, raw materials, products and wastes are designed to avoid open handling of materials and thus the exposure of operators, technicians and mechanics to 3-AP is controlled and negligible.

Both production lines and corresponding tank farms are well equipped with operational and monitoring devices to control and adjust process parameters (pressure, temperature, liquid level, flows, etc.). Safety instrumented systems are in place to prevent these parameters from reaching unsafe levels that could result in unacceptable risks to employees or the environment.

Product contamination due to product changeovers are obviated in both synthesis and distillation train by flushing all pieces of equipment with methanol and/or water depending on the solubility behavior of the previous product. The flushing media are sent via pipeline to incineration for disposal.

While producing 3-AP, only little waste water is generated which requires effluent treatment in the waste water treatment plant on site. Liquid waste streams resulting mainly from the distillation process are of organic nature and are collected in buffer tanks, until they are disposed of via the existing disposal systems for light and heavy boiling residues (pipeline and tank truck deliveries to residue incineration plant on site).

Exhaust piping from the synthesis and distillation train is connected to an incinerator of an adjacent production unit. To avoid air emissions of hazardous materials securely, the exhaust gas will be directed automatically to an emergency flare, should the incinerator fail.

Potential hazards for operators, technicians and mechanics, arising from any activities or tasks (e.g. sampling, loading/unloading of tank truck and rail cars, leak repair etc.) related to production assets are evaluated and documented in risk assessments and work permits. Safety procedures and exposure mitigation measures (e.g. personal protective equipment to wear) are in place.

 

Use as intermediate:

3-Aminopropanol (3-AP, CAS 156-87-6) is used as intermediate under strictly controlled conditions as a starting material for the synthesis of D-panthenol.Potential hazards for operators, technicians and mechanics, arising from any activities or tasks (e.g. sampling, loading/unloading of tank truck and rail cars, leak repair etc.) related to production assets are evaluated and documented in risk assessments and work permits. Safety procedures and exposure mitigation measures (e.g. personal protective equipment to wear) are in place.

 

Use in Gas Treatment and Charging and Discharging:

3-Aminopropanol (3-AP, CAS 156-87-6), in combination with other amines, is applied as an aqueous solution in closed-loop processes for capturing CO2from gas streams, mainly flue gas.

The gas stream containing CO2is introduced through an exhaust pipe into the purification plant. The exhaust gas in the exhaust pipe is introduced into a direct contact cooler where the exhaust gas is washed and humidified by counter-current flow to water. The cooled and humidified exhaust gas is then introduced into an absorber, where the exhaust gas is brought in counter-current flow to an aqueous absorbent solution (containing 3-AP and other amines) introduced through a lean amine pipe. Rich absorbent having absorbed CO2is collected at the bottom of the absorber and is withdrawn trough a rich absorbent pipe, whereas the CO2lean exhaust gas is released through a lean exhaust pipe after being washed in washing sections by means of water recycled through washing water cooling circuits. Because of extensive emission control systems and the relatively low volatility of 3-AP, the emission with treated flue gas will be very low and exposure to the public will be neglectable.

The rich absorbent is heated against the lean absorbent by means of a heat exchanger before being introduced into a regeneration column where the rich absorbent is stripped by counter-current flow to steam. The stripping steam is generated in a reboiler in which the lean absorbent collected at the bottom of the regeneration column is introduced through a lean absorbent withdrawal pipe.

Lean absorbent is withdrawn from the reboiler through the lean absorbent pipe and recycled into the absorber. Steam and CO2liberated from the absorbent in the regeneration column is washed in washing sections by counter-current flow to water recirculating in washing water cooling circuits, before being withdrawn through a CO2collection pipe. The CO2and steam are cooled in a condenser and condensed water is removed in a separator and recycled into the regeneration column through a recycling line. The partly dried CO2is withdrawn through a pipe for further treatment and downstream use.

The purification plant is equipped with sampling ports for gas and liquid, temperature and pressure probes and measurements of gas/liquid flow in all parts of the plant.

Waste products are incinerated, and waste water if any is routed to waste water treatment. Waste products are handled as hazardous waste by an approved waste handling company according to local regulations. Dedicated procedures are in place for all operating steps involving the substance handling, e.g. procedures for transfer of process inventory, draining of process units, clean-up of spillage, waste handling, etc.

Storage equipment such as the amine make-up tank for the process is sealed or nitrogen blanketed. The make-up tank could be charged a few times year from a road tanker/bulk transport with very limited exposure of workers due to the above described precautions. Accidental spills of 3-AP to the environment are avoided, as the purification plant is placed in a bunded area.

In view of the high degree of automation and closed nature of this process, exposure is limited to sampling procedures, cleaning and maintenance of equipment. Risk management measures are constantly applied by the highly trained and restricted personnel to minimize exposure.

 

Rigorous containment measures:

3-Aminopropanol (3-AP, CAS 156-87-6) is manufactured and used under strictly controlled conditions over the entire lifecycle. Exposure is limited to occasional sampling tasks for quality control, as well as to charging and discharging processes. Here, as well as during the handling for quality control analysis in the laboratory, risk management measures and stringent personal protective equipment are continuously applied. Transport, storage tanks, reactors, processing equipment, and feeds operate in fully closed systems.

  

Procedural and control technologies are used to minimize residual emissions/exposure as well as qualitative risk considerations:

Operational and technical conditions and measures affecting and controlling workers exposure, such as local exhaust ventilation as well as personal protective equipment, such as goggles, chemically resistant gloves, and respiratory protection where potential exposure may occur as reported in the CSR are followed (see chapters 9 & 10).

On the basis of the described process conditions, testing of 3-Aminopropan-1-ol in a reproduction toxicity (screening) study (OECD 421/422/415/416/443) was not performed since the criteria of exposure based adaptation of information requirements are met.

Justification for classification or non-classification

Classification, Labelling, and Packaging Regulation (EC) No 1272/2008
The available information on the test item regarding are reliable and suitable for classification purposes under Regulation (EC) No 1272/2008. Based on available experimental information, the test substance is not classified for toxicity to reproduction or developmental toxicity according to Regulation (EC) No 1272/2008 (CLP).

Additional information